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ABSTRACT 
 
 
Background: Consumers are exposed to thousands of advertisements, most all of which are 
designed to promote a particular brand and accompanying brand name. The selection of a 
brand name is a critical strategic decision and is an important means to building brand equity. 
The importance of branding elements, specifically brand names, has led pharmaceutical 
manufacturers to become more creative and open the possibilities of language in brand name 
development. Given the complexities associated with brand name development in the US 
pharmaceutical industry and the trends observed in recent pharmaceutical brand names, 
advancing the understanding of how brand name selection can affect patient judgments will 
be beneficial and extend previous research findings to this distinct arena. When consumers or 
patients see complex, often unfamiliar pharmaceutical brand names, the brand names alone 
may convey certain feelings and negative judgments, potentially affecting multiple aspects of 
the pharmacologic intervention. The purpose of this research was to explore the relationship 
between pharmaceutical brand name fluency and subsequent patient judgments associated 
with processing a pharmaceutical brand name. 
 
Methods: A total of 100 study participants were selected from a patient panel who have self-
reported rheumatoid arthritis. Study participants were assigned to one of two groups of 
pharmaceutical brand names, fluent or disfluent and then exposed to the associated 10 
pharmaceutical brand names. Participants were instructed to imagine they were reading the 
pharmaceutical brand name as part of an advertisement for the product and asked to assess the 
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perceived risk, familiarity, and willingness to request the pharmaceutical product from their 
physician. A two-condition between-subject approach was used for testing statistical 
significance of a single mediation model for the effects of fluency on perceived risk through 
familiarity. A moderated serial mediator model was incorporated to assess the effects of 
fluency and risk perception on willingness to request the product and to determine the 
moderating role of disease severity on the relationship between perceived risk and willingness 
to request. 
 
Results: Results showed that participants exposed to fluent brand names did not consider the 
products to be more familiar and there was no evidence that the fluency of the brand names 
influenced the perceived risk of the product independent of the effects of fluency on 
familiarity. Additionally, willingness to request the pharmaceutical product is not affected by 
the perceived risk of the product regardless of the level of disease severity. 
Conclusion: The current research is the first study to our knowledge that demonstrates 
pharmaceutical brand name fluency does not affect perceived risk of the product or willingness 
to request the medication in actual patients who are evaluating drug names indicated to treat 
their condition or disease. 
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CHAPTER I: INTRODUCTION 
 
Traditional Brand Name Development 
Research has indicated that on any given day, a person can be exposed to thousands of 
advertisements, most all of which are designed to promote a particular brand and accompanying 
brand name (Johnson 2006; Story 2007). Throughout many consumer product categories, brand 
names come in a multitude of forms. Such brand names are designed with a specific target market 
in mind, and the choice of the brand name is a critical strategic decision, requiring significant 
consideration. No matter the origin of a brand name or market for which the product is targeted, 
the choice of a brand name has been suggested as an important means to building brand equity 
(Aaker 1991; Keller et al. 1998). This is paramount to a brand’s profitability and sustainability 
because, in many of today’s fast-paced markets, it is difficult to maintain a competitive 
advantage on performance attributes alone (Kohli and LaBahn 1997). Such market dynamics 
require strong brand imagery to be established and leveraged. 
Extant literature suggests brands with strong brand images can influence choice and 
command a premium (Aaker 1991; Kohli and LaBahn 1997). The brand name is a fundamental 
part of brand image and considered the anchor for brand positioning initiatives (Kohli and 
LaBahn 1997). Recognizing the significance of a brand name, marketing research has proposed 
various normative approaches to developing and selecting an effective brand name. 
Keller et al. (1998 pg. 48) posited that selecting “inherently meaningful” brand names, 
such that the name itself conveys relevant product information, is one strategic opportunity to 
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enhance brand name awareness and identification within a product category. The researchers also 
prescribed a second strategy, which involves choosing a “suggestive” brand name (Keller et al. 
1998 pg. 48). The suggestive approach to brand naming is considered to facilitate and assist with 
positioning efforts. Additionally, Collins (1977) provided two basic naming strategies, which 
were referred to as the “Juliet Principle” and the “Joyce Principle.” The first strategy, the “Juliet 
Principle”, focuses on choosing a brand name and establishing the name in the consumers’ mind 
through repetition (Kohli and LaBahn 1997). The second strategy, the “Joyce Principle”, involves 
choosing a brand name that has the desirable phonetic symbolism for the product, which refers to 
the non-arbitrary relationship between sound and meaning (Kohli and LaBahn 1997). Although 
these examples and others within extant literature address many aspects of the brand naming 
process for conventional consumer products and categories, little focus has been directed towards 
the brand naming processes and implications of brand name selection within the pharmaceutical 
industry. 
 
Brand Name Development within the US Pharmaceutical Industry 
An effective pharmaceutical brand name has been considered by many researchers and 
marketing practitioners alike to play a critical role in building and maintaining customer loyalty 
and accordingly, as a very important element in contributing to the value and wealth creation of a 
pharmaceutical brand (Blackett and Robins 2001). Indeed, the brand name of a pharmaceutical 
product is likely the one element that will remain constant throughout the product’s lifetime. 
Because of this significance, many pharmaceutical manufactures spend considerable resources in 
developing and selecting the ideal brand name for their products (Russell 2007). However, unlike 
many consumer product categories, the development and choice of a pharmaceutical brand name 
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in the Unites States (US) has significant regulations governing the process. Pharmaceutical 
manufacturers do not have the same autonomy found within consumer-packaged goods (CPG) 
markets for brand name selection and, therefore, are limited in their ability to use many of the 
prescribed and aforementioned naming strategies found within the marketing literature. 
 
Regulatory Environment for Pharmaceutical Brand Name Development 
As US pharmaceutical manufacturers’ pipelines produce more diminished returns and 
overcoming the increasing use of generic alternatives becomes onerous, strategic focus on the 
development and management of a pharmaceutical brand becomes quite conspicuous. During the 
1980s and 1990s, naming a drug within the US pharmaceutical marketplace was less complex 
than today’s environment (Blackett and Robins 2001). Increases in the number of products 
entering the market and increases in the regulatory requirements put forth by the US Food and 
Drug Administration (FDA) regarding naming a pharmaceutical product have challenged 
companies attempting to successfully differentiate their products through brand name 
development. 
In recent years, the FDA has focused on increasing the safe use of drug products by 
minimizing user errors attributed to unclear nomenclature, labels, labeling and other packaging 
aspects of pharmaceutical products. This is primarily due to the growth in medication errors that 
has been realized throughout the US health system. Furthermore, as consumers become exposed 
to more and more pharmaceutical advertisements and pharmaceutical brand names, the role of the 
US FDA in reducing brand name confusion takes on an ever-growing importance (Fish and 
Richardson 2010). Pharmaceutical manufacturers must ensure that the investment associated with 
developing a brand name is not offset by failing to pass this FDA rigor of approving the name. 
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The Center for Drug Evaluation and Research (CDER) received approximately 126,000 reports 
of medication errors from 2000 – 2009, many of which were considered to be directly related to 
the similar sound and appearance of drug name pairs (FDA Guidance Document 2014). 
Additionally, there are approximately 3 billion retail prescriptions adjudicated annually in the US. 
Of these prescriptions, about 12.5% of medication errors are attributed to confusion by healthcare 
practitioners between drug names (World Trademark Review 2016). Because of this trend, 
CDER, a component of the US FDA, has developed and refined internal procedures for 
evaluating the potential for a proposed brand names to cause or contribute to medication errors as 
part of the Center’s focus on the safe use of drug and therapeutic biologic products (FDA 
Guidance Document 2014). 
The review of proposed pharmaceutical brand names is conducted by the Division of 
Medication Error Prevention and Analysis (DMEPA) in CDER’s Office of Surveillance and 
Epidemiology (OSE). The Office of Prescription Drug Promotion (OPDP), formerly the Division 
of Drug Marketing, Advertising, and Communications (DDMAC), works in consultation with 
DMEPA to determine the acceptability of proposed pharmaceutical brand names seeking 
marketing approval. These regulatory agencies provide broad guidance to manufacturers, which, 
if followed, will increase the likelihood of acceptance or approval of a proposed pharmaceutical 
brand name. 
Adding to the complexity associated with brand naming processes in the US 
pharmaceutical industry, pharmaceutical manufacturers must also be cognizant of the generic 
name of the pharmaceutical product, which differs from the brand name or trade name. In the US, 
the generic name of the pharmaceutical product is a by-product of the USAN, which stands for 
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the United States Adopted Name. The USAN is obtained through collaboration with the United 
States Adopted Names Council (USANC), which serves the health profession in the US by 
selecting simple, informative, and unique nonproprietary names (i.e. “stems”) for drugs by 
establishing logical nomenclature classifications based on pharmacological and chemical 
relationships (AMA 2016). A pharmaceutical manufacturer is responsible for applying and 
receiving approval for a USAN (typically completed in Phase II) before the brand name can be 
filed with the FDA. Although the generic name is not always translated directly into the 
pharmaceutical brand name, many products have traces of the generic name or ‘stem’ in the 
brand name. One famous example of this naming strategy exist with the product Lipitor, which 
combines a portion of the word “lipid” with a portion of the stem “-tor” from the generic name 
(atorvastatin). 
 
Brand Naming Trends within the US Pharmaceutical Industry 
It becomes apparent that within the US pharmaceutical industry, manufacturers are 
wedged between the tried-and-true brand naming strategies that extant marketing literature 
prescribes and the stringent boundaries that are imposed by regulatory bodies responsible for 
approving pharmaceutical brand names. Due to these peculiar market conditions, one is left to 
wonder just how pharmaceutical brand names are actually created and how these names are 
perceived by prescribers and patients. Although there are a host of opinions and difficult to 
decipher meanings in pharmaceutical brand name development, there has been little consensus 
among firms in approach. Trends in pharmaceutical brand names have been noted among choices 
that make use of linguistic tricks such as plosive letters ‘P’, ‘T’, and ‘D’ in an effort to convey 
power (Ipaktchian 2005). Other trends have been observed with the use of fricative letters such as 
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‘X’, ‘F’, ‘Z’, and ‘S’ to imply speed (Ipaktchian 2005). This, in part, helps explain the number of 
Xs and Zs that have been present within drug names in recent years. 
The importance of branding elements, specifically brand names, has led pharmaceutical 
manufacturers to become more creative and open the possibilities of language in brand name 
development. More classic vowel/consonant constructions have ceded to more “innovative” 
approaches, such as the conjunction of consonants seen with products like Vfend and Qvar  
(Blackett and Robbins 2001). Such unnatural brand names may seem “strategic” at first glance 
but could end up being problematic in more ways than imagined. Many of the new generation 
drug names can be hard to spell and more importantly hard to pronounce. 
Given the complexities associated with brand name development in the US 
pharmaceutical industry and the trends observed in recent pharmaceutical brand names, 
advancing the understanding of how brand name selection can affect patient judgments will be 
beneficial and extend previous research findings to this distinct arena. That is, when consumers or 
patients see complex, often unfamiliar pharmaceutical brand names, the brand names alone may 
convey certain feelings and negative judgments. Such judgments and perceptions of 
pharmaceutical products inferred through the brand name could potentially affect multiple 
aspects of the pharmacologic intervention, to include treatment choice, willingness to inquire 
about the medication, primary adherence, and other important and associated outcomes. If 
evidence supports that such feelings are indeed associated with certain pharmaceutical brand 
names, this could prove to be harmful to advertisement initiatives that are intended to promote 
patient and physician dialogue. Patients may shy away from asking about or discussing a 
potentially beneficial pharmaceutical product with their healthcare provider simply because of 
the brand name. Furthermore, these unintended consequences of pharmaceutical brand name 
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judgments could easily be avoided by considering the risk perceptions of consumers and patients 
in brand name development initiatives. 
 
Study Aims 
The broad purpose of this research is to explore the relationship between pharmaceutical 
brand name fluency and subsequent patient judgments associated with processing a 
pharmaceutical brand name. To achieve these broad objectives, the study had the following aims: 
 
1. To evaluate the perceived risk associated with a pharmaceutical product based on the 
pharmaceutical brand name fluency. 
 
2. To investigate whether the effects of linguistic fluency on perceived risk is mediated by 
patients’ perceived familiarity of the pharmaceutical brand name. 
 
3. To assess the effects of linguistic fluency and risk perception associated with 
pharmaceutical brand name fluency on a patient’s willingness to request a pharmaceutical 
product. 
 
4. To assess whether disease severity moderates the relationship between perceived risk and 
patients’ willingness to request a pharmaceutical product. 
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CHAPTER II: REVIEW OF LITERATURE AND CONCEPTUAL FRAMEWORK 
 
Processing Fluency 
Human judgment reflects not only the content of our thoughts but also the metacognitive 
experience of processing the thoughts (Alter and Oppenheimer 2009). Many theories involving 
consumer judgments make the assumption that peoples’ judgments are formed based on 
informational aspects that are pertinent to the target and serendipitously come to mind at the time 
of evaluation  (Schwarz 2004). If this were indeed the case, consumers would ideally assess a 
product more favorably when more positive attributes of the product come to mind. Similarly, 
from a normative perspective, consumers should evaluate the validity of a product claim by 
drawing on relevant accessible knowledge about the respective content domain (Schwarz 2004). 
Based on this rationale, a pharmaceutical product which includes the most superior efficacy and 
safety data, would surely “win” in the minds of patients when direct-to-consumer advertising is 
conducted. Empirical evidence does not support this proposition and research surrounding 
metacognitive experiences in consumer judgment and decision-making provides some 
explanation into this matter. 
Consumers’ thought processes are guided by metacognitive experiences, such as the ease 
or difficulty with which the information presented can be brought to mind or the fluency with 
which new information can be processed (Schwarz 2004). Because of this, research has 
demonstrated that an individual’s judgment often departs from what one would predict based on 
the accessible declarative information (Schwarz 2004). Schwarz (2004) posited that such findings 
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show that the subjective experiences that accompany the thought process qualify the implications 
of accessible declarative information, sometimes to the extent that the judgment is paradoxical to 
what the accessible content would suggest. 
Schwarz (2004) concluded that based on an individual’s metacognitive experiences, the 
person’s conclusion depends on their naïve theories of memory and cognition. In other words, an 
evaluation is based on an individual’s assumption about just how easy or difficult the stimulant 
causes one to think of certain things or to process new information. This assertion is intriguing 
and relevant to the development of pharmaceutical brand names, especially at it relates to 
consumers who are intrinsically less informed and knowledgeable about the specific utility and 
clinical attributes of drug therapies. The issue becomes more concerning when considering the 
increasing level of exposure that many consumers have to drug names and advertisements. 
Additional research regarding the effects of processing fluency may help shed light on this issue. 
Lee (2004) extended the work by Schwarz (2004) and proposed that the metacognitive 
route to judgment could occur more often that Schwarz first suggested. More specifically, Lee 
(2004) refined Schwarz’s examination regarding the effects of processing fluency on judgments 
of liking and preference by making salient the distinction between how individuals process a 
target and how individuals process information about the target. 
Schwarz (2004) posited that an individual’s metacognitive experience may be the basis for 
judgments of truth, but the individual’s positive experience of processing fluency actually drives 
judgments of preference (Lee 2004; Schwarz 2004). In other words, Lee (2004) hypothesized that 
an individual’s attitude toward a target (e.g. the brand) will become more favorable when the 
target is perceptually fluent. In a thorough review of the literature surrounding this topic, Lee 
(2004) concluded that judgments often depend on how easy it is for an individual to process the 
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target rather than information about the target at the time of evaluation. In addition to the work by 
both Lee (2004) and Schwarz (2004) regarding processing fluency, other research has argued that 
processing fluency is one component of fluency but other forms of fluency should also be 
considered when addressing the effects of subjective feelings or ease of fluency. 
 
Additional Forms of Fluency 
Researchers have addressed the broad construct of fluency in various manners since 
Schwarz (1990) showed that fluency influences judgment independently of the retrieved content 
that accompanies the experience of fluency. Alter and Oppenheimer (2009) summarized the idea 
of fluency by positing that every cognitive task can be described along a continuum from 
effortless to highly effortful, which produces a corresponding metacognitive experience that 
ranges from fluent to disfluent. The researchers went on to further categorize the various 
byproducts or forms of fluency including perception, memory, embodied cognition, linguistic 
processing, and higher order cognition (Alter and Oppenheimer 2009). Using this classification 
(Figure 1), it is the specific aspects of linguistic processing that are of interest as it relates to the 
effects of pharmaceutical brand names on patient perceptions. 
   
1
1
 
 
 
Figure 1: Classification of Various Instantiations of Fluency 
 
 
 
 
 
 
 
 
Source: Alter and Oppenheimer 2009 
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The Components of Linguistic Processing and Effects on Fluency 
One area of linguistic fluency that has been addressed by prior research and will be further 
examined within this research is phonological fluency. Simply put, certain letter strings are easier 
to process than others (Alter and Oppenheimer 2009). Phonological fluency helps explain why 
the difficulty, or lack thereof, in pronouncing certain names engenders the experience of 
disfluency. Research has indicated that English speakers struggle to pronounce certain names and 
obscure words and that these experiences translate into intriguing judgments (Alter and 
Oppenheimer 2009). 
Alter and Oppenheimer (2006) investigated the impact of phonological fluency on the 
ability to predict short-term stock share fluctuations. In coordination with prior research findings, 
Alter and Oppenheimer (2006) hypothesized that when people attempt to understand complicated 
information, they often simplify the task by relying on mental shortcuts, or heuristics. In other 
words, the researchers wanted to analyze whether people tend to judge stimuli that were fluent, or 
in this case easy to pronounce, more positively on a range of evaluative dimensions (Alter and 
Oppenheimer 2006). By manipulating phonological fluency through the complexities of 
fabricated stock and company names, or how easy the names were to pronounce, the researchers 
were able to demonstrate that people prefer to invest in stocks and the companies with fluent 
rather than disfluent names (Alter and Oppenheimer 2006). Additionally, the researchers sought 
to support these findings by analyzing actual market data based on the ease of pronunciation of 
ticker codes as a predictor of actual stock performance (Alter and Oppenheimer 2006). The 
findings aligned with prior studies and showed that shares with pronounceable ticker codes 
outperformed those with unpronounceable ticker codes. 
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With similar research aims in mind, Laham et al. (2012) addressed phonologic fluency by 
investigating what the researchers coined as the name-pronunciation effect. This phenomenon is 
essentially synonymous with the construct of phonologic fluency that other research has 
addressed but differs slightly by levering the hedonic marking hypothesis (Winkielman et al. 
2003). Simply put, the researchers posited that experiencing a name activates a rich set of 
semantic information, which impacts impression formation and evaluation (Laham et al. 2012). 
Throughout a series of experiments in a range of laboratory settings, the researchers demonstrated 
the name-pronunciation effect and found that easy- to-pronounce names are evaluated more 
positively than difficult-to-pronounce names. This effect was even realized in one experiment by 
demonstrating that subjects rated one potential candidate running for office as more suitable than 
another, with all information presented held constant except for the ease of pronunciation of the 
candidate’s name (Laham et al. 2012). One of the most important takeaways from this research 
and one that is not addressed in similar research is that the researchers were able to demonstrate 
the robustness of fluency effects, even in potentially information-rich contexts. This is relevant 
to the current research in that consumers often have access to other information in addition to the 
pharmaceutical brand name. Some may argue that because consumers often make judgments 
about a pharmaceutical product in an information-rich environment, the brand name and 
associated linguistic fluency may contribute little to impression formation. The work by Laham 
et al. (2012) was able to demonstrate that the name pronunciation impacts liking and other 
evaluative measures strongly and consistently, even when other cues are accessible. 
A considerable amount of research has evaluated phonologic fluency associated with 
names and found that people tend to prefer easy to pronounce names over difficult to pronounce 
names (Song and Schwarz 2009; Alter and Oppenheimer 2006, 2009). After reviewing social 
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psychology and consumer behavior literature, these relationships may seem intuitive. However, 
one may ask why does this phenomenon matter and how does it relate to brand naming trends 
among pharmaceutical products? An inspection of additional research regarding fluency and 
perceived risk helps to connect the dots. 
 
Effects of Fluency on Familiarity and Perceived Risk 
Since the initial introduction to the marketing literature of the concept of perceived risk, 
many researchers have focused on levering the ideas of risk and risk reduction (Bauer 1960; 
Bettman 1973). Perceived risk has been defined as the expectations of losses associated with a 
decision or purchase (Ganther and Kreling 1999). The concept of loss can be a monetary loss or a 
non-monetary loss. Bettman (1973) posited that there are two main components to perceived risk: 
the chance component, which refers to the probability of a loss, and the severity component. 
It has also been demonstrated that people respond differently to the hazards that they 
perceive (Slovic et al. 1981). Some perceived hazards are accompanied with extensive objective 
evaluative inputs while others may be based on direct experience. Despite some instances of 
objectivity, all forms of risk assessment are considered to include a large component of subjective 
judgment (Slovic et al. 1981). Accordingly, consumers are often asked to evaluate risks in 
situations where they seldom have in-depth evidence on hand to support their judgments. In these 
types of positions, extant literature has identified a number of general inferential rules that people 
use (Slovic et al. 1981). These rules are referred to as heuristics and are used to reduce difficult 
mental task to simpler ones or mental shortcuts (Slovic et al. 1981). This particularly important 
implication directly relates to the perceived risks people may deduce, which can be affected by 
processing fluency. 
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Slovic et al. (2004) addressed the affective components of risk, which is the specific 
quality of goodness or badness experienced as a feeling of state, with or without consciousness. 
The researchers posited that affective responses occur rapidly and automatically and that the 
reliance of such feelings could be characterized as “the affect heuristic” (Slovic et al. 2004). 
Affect plays an important role in what literature suggests as the dual-process theories of thinking, 
knowing, and information processing (Chaiken and Trope 1999; Kahneman and Fredrick 2002; 
Sloman 1996; Slovic et al. 2004). These two routes are referred to as the experiential and analytic 
systems. 
One of the main characteristics of the experiential system is its affective basis (Slovic et 
al. 2004). Zajonc (1984) posited that affective reactions to stimuli are often the first reactions to 
stimuli, occurring automatically and subsequently guiding information processing and judgment. 
Even though analysis is important in some decision-making situations, reliance on affect and 
emotions is quicker, easier, and more efficient. Studies indicate that even though risk and benefit 
tend to be positively correlated in the world, they are negatively correlated in people’s minds 
(Slovic et al. 2004; Fischhoff et al. 1978). In other words, people base their judgments of an 
activity or technology not only on what they think but also on how they feel about it (Alhakami 
and Slovic 1994; Slovic et al. 2004). These findings are important for the current research such 
that if consumer feelings toward processing a brand name are favorable, then they may likely be 
moved toward judging the risks as low and the benefits as high. 
Song and Schwarz (2009) sought to extend prior research surrounding risk perception 
(Lowenstein et al. 2001), which conceptualized ordinary risk judgment as one that is an intuitive 
rather than analytic process, involving the role of feelings such as like, fear, and anxiety in risk 
perception. The researchers did so by exploring how fluency contributes to the concept of “risk as 
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feelings” (Slovic et al. 2004; Song and Schwarz 2009). Extant literature has demonstrated that 
information that is fluent is perceived as more familiar and therefore evokes a more positive 
affective response than disfluent information (Schwarz 2004). The logic behind these findings is 
that because familiar material is easier to process than novel material, consumers infer familiarity 
from ease of processing (Pocheptsova et al. 2010; Song and Schwarz 2009). It has been 
demonstrated that in general, consumers will attribute the metacognitive difficulty experiences 
when processing information or thinking about an advertised product to unfamiliarity with the 
product (Pocheptsova et al. 2010). 
Researchers believe that the positive impact of metacognitive ease of processing on 
evaluative judgments is due to a perceived connection between ease and familiarity or between 
difficulty and unfamiliarity (Song and Schwarz 2009). 
Accordingly, Song and Schwarz (2009) hypothesized that if apparent familiarity does 
indeed play a prominent role in intuitive judgments of risk, then novel information or stimuli 
should be perceived as less risky when the information is easy rather than difficult to process. By 
using ease of pronunciation to manipulate processing fluency, Song and Schwarz (2009) 
demonstrated that people perceive disfluently processed stimuli as riskier than fluently processed 
stimuli. The findings for this research extend prior work by suggesting that fluency 
manipulations, and specifically ease of pronunciation, may shed light on management of 
perceived risk (Song and Schwarz 2009). In other words, disfluent product names may infer risk, 
erroneously or not, to a consumer simply based on the ease of pronunciation of the brand name. 
 
Phonetic Effects and Heuristic Cues of Brand Names 
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Literature indicates that a specific component of linguistic fluency is phonological fluency 
(Alter and Oppenheimer 2009). The relevant aspect to phonological fluency in regard to the goals 
of this research stems from the belief that phonetic symbolism, or the relation between sound and 
meaning (Lowrey and Shrum 2007), conveys certain cues to a person. The idea that the mere 
sound of a word, apart from the actual definition, has itself meaning and is important to brand 
name selection. Such sounds are derived from phonemes, which are the smallest units of a sound 
(i.e. the sound of an individual letter). Sound symbolism has been recognized as an important 
factor in how a person infers specific meaning from a brand that is considered as unfamiliar 
(Yorkston and Menon 2004). Although marketing researchers might have been aware of the 
presence of sound qualities in names, the work by Klink (2000, 2001, 2003) first applied the 
principles of phonology to marketing research. Klink investigated the idea that different vowels 
and consonants are articulated in different areas of the mouth (e.g. front of mouth or back of 
mouth) and that such front/back articulation affects consumers’ perceptions of the quality of the 
sound in a name, thereby inducing inferred attributes in the brand name of a product. 
In building upon the work by Klink (2000, 2001, 2003), Yorkston and Menon (2004) 
hypothesized that if a brand name contains phonemes that represent attributes a consumer desires, 
then the consumer will hold more positive attitudes and exhibit higher purchase intentions toward 
that brand. The researchers were able to demonstrate through two different experiments, 
manipulating a single vowel sound in a brand name, the process by which sound symbolism 
manifests in consumer judgments and that the process is incontrollable, outside of awareness, and 
effortless, therefore making it automatic (Yorkston and Menon 2004). Furthermore, this research 
seems to indicate that sound symbolism, although evaluated on the attribute level, affects overall 
 18  
evaluations. 
Additional research has indicated that certain sounds seem to be consistently related to 
concepts such as disgust or dislike in the English language (Jespersen 2013; Lowrey and Shrum 
2007). If this is indeed occurring in the minds of consumers, then brand names that contain these 
sounds might also be regarded as negative (Lowrey and Shrum 2007). 
Indeed, Smith (1998) demonstrated this logic through an experiment using names of candidates 
containing vowel sounds that are used to express disgust and candidate names that might be less 
favorably perceived. By constructing a “comfort index” surrounding phonetics and analyzing US 
presidential election outcomes, beginning in 1824 through 1992, he found that the candidate with 
the highest comfort index won the popular vote in 35,      or 83%, of the elections (Smith 1998). 
He then extended this analysis to local elections, US Senate and House elections and found 
overwhelming evidence that favorably named candidates won a majority of elections over less 
favorably named candidates (Smith 1998). 
 
The Effects of Fluency within the Pharmaceutical Marketplace 
Although research assessing the effects of brand name fluency within the pharmaceutical 
marketplace is limited, recent research has emerged which helps to demonstrate the impact of 
pharmaceutical brand names on consumers’ evaluations and behavioral intentions. Dohle and 
Siegrist (2013) examined the impact of a pharmaceutical’s brand name on evaluations and 
behavioral intentions, appealing to the representativeness heuristic and fluency theory. In a series 
of experiments on a student population with hypothetical scenarios, the researchers demonstrated 
that participants judged pharmaceutical products with simple names as safer and were more 
willing to buy the products. Additional research by Tasso, Gavarzzi, and Lotto (2014) 
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investigated whether drug names affect judgments surrounding efficacy, risk, and other properties 
associated with the products. In a series of experiments, the researchers found evidence to support 
the notion that the name of a drug may involve a promise, influencing the perceived power of the 
product and that this psychological power is conveyed through persuasive drug names (Tasso, 
Gavarzzi, and Lotto 2014). Cho (2014) extended the work by Dohle and Siegrist (2013) by 
exploring the malleability of the name fluency effect on pharmaceutical drug perception by 
examining the fluency effect in the domain of risk versus advancedness judgment. In an 
experiment among students, the researchers were able to demonstrate that the simplicity or 
complexity of a drug name can affect patient perceptions, evaluations, and potentially 
medication-use behaviors. Finally, Dohle and Montoya examined the effects of processing 
fluency for pharmaceutical brand names on dosing behavior (Dohle and Montoya 2017). In two 
experiments among university students and survey panel participants in Europe, the researchers 
demonstrated that fluent drug names resulted in lower dosage of drugs compared to disfluent 
names (Dohle and Montoya 2017). However, their experiments did not find support for the 
previously presented evidence for the mediating role of familiarity to the fluency-risk relationship 
(Dohle and Montoya 2017). 
Aligned with the increasing body of research surrounding the effects of fluency, with 
specific focus aimed at the unique aspects of the US pharmaceutical industry, the aim of this 
research was to assess the effects of pharmaceutical brand name fluency on familiarity and 
perceived risk. More specifically, and as demonstrated by Song and Schwarz (2009), this study 
assesses the effects of linguistic fluency associated with pharmaceutical brand names on a 
patients’ perceived risk of the product. Furthermore, this study addresses the role of familiarity as 
a possible mediating variable to this relationship. 
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The Effects of Disease Severity on Patient Acceptance of Perceived Risk 
It is apparent from the prior discussion surrounding various effects of fluency that both lay 
consumers and patients may derive certain judgments about a pharmaceutical product simply 
based on the brand name. This is an important component to this research; however, it is also 
important to consider the effects of disease severity on patients’ judgments. Most pharmaceutical 
products are accompanied by both the possibility of therapeutic or desirable effects and the 
possibility of adverse events or undesirable effects. Because of this, healthcare providers often 
attempt to use the attitudes of patients regarding the risks and benefits of a drug as one factor in 
their choice of therapy (Eraker and Sox 1981). From the patient’s perspective, perceived risk and 
their willingness to proceed down a particular treatment path may be influenced by the severity 
of their condition. Much of this cognitive process may be explained through adaptation theory 
and the hedonic treadmill theory. 
Brickman and Campbell (1971) described the hedonic treadmill as a process similar to 
sensory adaptation with people’s emotional reactions to life events (Diener, Lucas, and Scollon 
2006). The researchers posited that one’s emotion system adjusts to one’s current life 
circumstances and that all reactions are relative to one’s prior experience (Brickman and 
Campbell 1971; Diner, Lucas, and Scollon 2006). This was characterized in the work by 
Brickman, Coates, and Janoff-Bulman (1978) when the researchers showed empirical support for 
the treadmill model. They concluded that lottery winners were not happier than non-winners and 
that people with paraplegia were not substantially less happy than those who could walk 
(Brickman, Coates, and Janoff-Bulman 1978; Diner, Lucas, and Scollon 2006). Relevant to this 
research, the idea of hedonic adaptation aids in understanding how different patients may have 
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conflicting responses to the perceived risks associated with a particular pharmaceutical product 
based on their state of well-being and the severity of their disease. 
In following this logic, Johnson et al. (2009) assessed whether adult patients are more 
tolerant of treatment risks than parents of juvenile patients and found that adult patients and 
parents of juvenile patients with Crohn’s disease (CD) were willing to accept similar levels of 
severe adverse event risk. The authors posited that these findings might be explained by 
adaptation theory (Johnson et al. 2009). In their position for using adaptation theory to explain 
this finding, the researchers explained that patients with less serious cases have to imagine what it 
would be like to have more serious symptoms and that because patients with more severe cases 
often learn to adapt over time, more serious symptoms may not be as detrimental to quality of life 
as the less sever patients imagine (Johnson et al. 2009). In fact, Johnson et al. (2007) found that 
patients with more severe CD are actually less tolerant of severe adverse event risk than patients 
with less severe CD. The  researchers also found that patients whose symptoms had little or no 
effect on their activities of daily living were willing to take more risks compared with patients 
who reported considerable problems in daily activities (Johnson et al. 2007). 
Other research surrounding patients’ assessments towards and willingness to take risks 
associated with pharmaceutical products has demonstrated conflicting evidence to these findings. 
For example, Lacy et al. (2012) explored patients’ risk-taking behavior and their willingness to 
take medication risks in irritable bowel syndrome (IBS). The researchers found that IBS patients 
with severe symptoms were more willing to take significant medication risks that those with mild 
or moderate symptoms, which is in direct contrast to the studies within CD (Lacy et al. 2012). 
Specific to rheumatoid arthritis, research has indicated a pattern of reluctance in arthritis patients 
to accept the risk of drug-related adverse effects. Fraenkel et al. (2001) found that in general, 
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rheumatoid arthritis patients are very concerned about potential drug toxicity. The researchers 
demonstrated that risk adversity appeared to be attenuated by a patient’s past experience with 
adverse events and that patients with milder disease activity may be more hesitant to accept 
commonly used medications if they are aware of potential adverse events (Fraenkel et al. 2001). 
Throughout multiple conditions and across various types of pharmacologic options, the 
literature demonstrates mixed findings in the extent and direction to which disease severity can 
affect patients’ judgments and willingness to pursue a treatment option. This may in part be due 
to the nature of the symptoms associated with a condition as some symptoms become more 
apparent than others. Addressing these individual differences among various conditions is outside 
the scope of this current research. However, it is clear that the disease severity of a patient can 
indeed affect the perceived risks and willingness to pursue a pharmaceutical intervention. 
Because of this, it is considered relevant and necessary to include disease severity as a 
component to the assessing the effects of fluency on judgments with a specific patient population 
and accordingly, will be included in this current proposal. 
 
The Effects of Fluency and Perceived Risks on Patient Medication Requests 
Although direct-to-consumer advertisements (DTCA) for branded pharmaceutical 
products are a marketing tactic, designed to increase market share of a particular product over a 
competitive alternative, a potentially positive effect of advertisements lies in the idea that the ads 
may encourage patients to visit their healthcare providers to inquire about the medical condition 
and therapeutic options for treatment (Sinkinson and Starc 2015). This marketing channel 
addresses the changes in patient behavior, such that in recent decades, patients have become more 
active participants in their medical care (McKinlay et al. 2014). In fact, since the FDA began 
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allowing DTCA in 1997, research has indicated that approximately 30% of Americans talk with 
their doctor about a medicine they saw advertised, of whom approximately 44% report that their 
doctor prescribed the medication requested (Berger et al. 2001; McKinlay et al. 2014). 
Active requests from patient to provider regarding specific medications have been 
demonstrated to significantly affect prescribing behavior. For example, in a study by McKinlay 
and colleagues, one in five physicians reported that they would prescribe oxycodone to patients 
requesting the drug (for sciatica patients) compared to only 1% of physicians who viewed the 
same clinical scenario with a patient who made a passive request for pain relief (McKinlay et al. 
2014). 
 
General Study Purpose 
As demonstrated in previous research and findings from a review of the literature, brand 
names are considered to be a critical component to establishing a brand’s equity and competitive 
advantage in the marketplace. Because of the significance of brand names in a product’s 
marketing effectiveness, extant literature has proposed various normative approaches to 
constructing brand names. Although such strategies may be leveraged in many consumer product 
categories, pharmaceutical manufacturers do not have the autonomy to employ such prescribed 
brand naming methods. Because of the intricacies within the pharmaceutical market, there has 
been little consensus regarding effective brand naming strategies among pharmaceutical 
manufacturers, resulting in a variety of pharmaceutical brand naming tactics, considered by many 
to be complicated and difficult to pronounce brand names. 
Given the complexities associated with pharmaceutical brand names, advancing 
understanding of how brand name selection may affect patient judgments and calls to action will 
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be beneficial to the healthcare community and pharmaceutical manufacturers, while also 
extending previous findings to this important field. Thus, the general focus of this research is to 
understand the relationship between the fluency associated with pharmaceutical brand manes and 
patient perceptions and judgments that are experienced while processing the brand names. 
 
Specific Aims and Hypotheses 
In order to meet the specific aims previously listed, the study sought to test the following 
sets of hypotheses based on the literature: 
 
Aim 1: Evaluate the perceived risk associated with a pharmaceutical product based on the 
pharmaceutical brand name fluency. 
H1a: There is a statistically significant relationship between the linguistic fluency of individual 
pharmaceutical brand names and patients’ perceived risk of the pharmaceutical product. 
 
Aim 2: Investigate whether the effects of linguistic fluency on perceived risk is mediated by 
patients’ perceived familiarity of the pharmaceutical brand name. 
 
H2a: The relationship between linguistic fluency of the pharmaceutical brand names and perceived 
risk is mediated by familiarity. 
 
Aim 3: Assess the effects of fluency and risk perceptions on willingness to request 
H3a: There is a statistically significant relationship between linguistic fluency and a patient’s 
perceived risk of a pharmaceutical product and the patients’ willingness to request a 
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pharmaceutical product. 
 
Aim 4: Assess whether disease severity moderates the relationship between perceived risk 
and patients’ willingness to request a pharmaceutical product 
H4a: Disease severity moderates the relationship between the perceived risk of a pharmaceutical 
product and willingness to request the pharmaceutical product. 
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CHAPTER III: METHODS 
 
Using a non-scientific website (Wordlab Drug-O-Matic Name Generator 2016), 45 
randomly generated, fictitious pharmaceutical brand names were developed. The pharmaceutical 
brand names differed in length, consonant and vowel frequencies, and beginning letter selection. 
The goal of the process was to develop a thorough list of names that could be tested in a pre-test 
setting with consumers and then subsequently used in the experiment with patients. The purpose 
of creating fictitious names was to use the pharmaceutical brand names to measure the various 
effects of fluency on patient judgments, without bias to prior exposures or experiences with 
branded pharmaceutical products. 
 
Measuring the Construct of Fluency 
As previously discussed, the broad construct of fluency can refer to virtually any cognitive 
task described along a continuum from effortless to highly effortful, which then produces a 
corresponding metacognitive experience that can be described along a continuum from fluent to 
disfluent (Alter and Oppenheimer 2009). For the purposes of this research, fluency was defined as 
the ease of pronunciation of the fictitious pharmaceutical brand names. 
Accordingly, an ease of pronunciation measure was incorporated as a proxy measure for the 
construct of linguistic fluency. 
 
Pre-test 
Having established the 45 fictitious pharmaceutical brand names, pre-testing the names for 
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ease of pronunciation was conducted. A pre-test survey was fielded using Amazon's Mechanical 
Turk (MTurk). Participants followed a link to the survey. Briefing instructions were provided and 
participants were asked to rate the ease of pronunciation of the 45 pharmaceutical brand names. 
Pre-test participants were asked to rate the ease of pronunciation of the pharmaceutical brand 
name products individually using the 7-point response scale. Fluency was measured by having 
participants rate the ease of pronunciation of the fictitious pharmaceutical brand products. This 
measure was captured using a single- item interval response scale ranging from 1 = very difficult 
to pronounce, 7 = easy to pronounce with each scale value between poles labeled (appendix A). 
Once the ratings for all 45 products were obtained, the pharmaceutical brand names were 
categorized based on the level of fluency ratings. This provided two groups of 10 pharmaceutical 
brand names based on fluency ratings that were used to manipulate fluency in the forthcoming 
experiment: one group of easy-to-pronounce names and one group of difficult-to-pronounce 
names. 
In order to assess that the two groups of names were statistically different from one 
another, a t-test was conducted to compare the easy to pronounce group with the difficult to 
pronounce group. The a priori significance level (alpha) was set at 0.05. Although participation 
in the pretest was voluntary, an Institutional Review Board (IRB) application was obtained 
before commencement of the pretest and subsequent research. 
 
Sample Selection 
A total of 100 study participants were selected from a patient panel maintained by L&E 
Research. The patient panel is voluntary and comprises approximately 1,000 patients who have 
self-reported rheumatoid arthritis (RA). Payments to patients are provided for individual study 
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participation only and not for membership on the panel. Study participants were required to be 18 
years of age or older, have a self-reported diagnosis of RA, and speak English. The selection 
criteria and online survey link were provided to L&E Research with a target sample of 100 
participants. 
 
Procedure 
Using the 20 pharmaceutical brand names (10 easy to pronounce and 10 difficult to 
pronounce) determined as a result of the pre-test, study participants were assigned to one of two 
groups of pharmaceutical brand names, fluent or disfluent. Participants in each group were then 
exposed to the associated 10 pharmaceutical brand names, with order of the pharmaceutical brand 
names presented randomly. Similar to the procedures used for the pre-test, briefing instructions 
were provided at the beginning of the survey and participants were asked if they understood 
everything, and were ready to begin the procedure. At the end of the experiment, participants 
were provided debriefing information. 
Since the participants in the study were not asked to rate the level of fluency associated 
with the pharmaceutical brand names as part of the main experiment, it was important to ensure 
fluency was indeed being manipulated. Accordingly, a manipulation check for the independent 
variable of fluency for the pharmaceutical brand names was included at the end of each survey 
for both groups. To conduct the manipulation check, participants from each group rated the 
fluency for each of the ten associated pharmaceutical brand names. The fluency ratings for fluent 
and disfluent groups were compared to data from the pre-test subjects to ensure the perceptions 
of fluency were not statistically different. A directional t- test was performed comparing pre-test 
mean ratings for both fluent and disfluent name ratings. 
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Perceived Risk 
 
Participants were instructed to imagine they were reading the pharmaceutical brand name 
as part of an advertisement for the product and asked to assess the perceived risk they believe was 
associated with the pharmaceutical product based solely on the brand name. Perceived risk was 
conceptualized as physical risk. More specifically, participants were asked to rate the level of 
concern they would have about using the product based on the brand name (Stone and Gronhaug 
1993). The measure was captured on a 7-point scale ranging from 1 = very harmful, 7 = very 
safe. 
 
Familiarity 
In addition to rating the perceived risk the participants associated to the pharmaceutical 
brand name, participants were also asked to rate the perceived familiarity of the products based 
on the pharmaceutical brand name. To capture the construct of familiarity, a proxy measure of 
perceived novelty of the product was assessed using a single item interval response scale ranging 
from 1 = very old, 7 = very new. The brand name of the pharmaceutical products was the only 
stimuli presented (appendix C). 
 
Disease Severity 
Disease severity is hypothesized as moderating the relationship between perceived risk 
and willingness to request a pharmaceutical product. In order to capture the moderating variable 
of disease severity, a portion of the Health Assessment Questionnaire Disability Index (HAQ-DI) 
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was administered. Two visual-analog scale (VAS) items within the HAQ-DI to assess pain and 
health were incorporated as a global assessment of disease severity. Participants were asked to 
indicate how much pain they had because of their RA in the past week on a scale of 0 to 100, 
where zero represents “no pain” and 100 represents “severe pain”. Participants were also asked to 
consider all of the ways their arthritis affects them on a scale of 0 to 100, where zero represents 
“very well” and 100 represents “very poor” health. The two VAS items were summed to form the 
measure of disease severity for each participant. 
 
Willingness to Request 
The participants’ willingness to request the pharmaceutical products served as the 
dependent variable in the study. The goal of this measure was to investigate the effects of 
fluency, perceived risk, and disease severity on a patient’s willingness to request the product to 
which they have been exposed to in a promotional channel. 
Similar measures of willingness regarding the use of pharmaceutical products have been 
assessed in extant literature. For example, Peters and colleagues (2014) investigated various 
formats for presenting medication risk information as it relates to a patient’s willingness to take 
the drug. In their study, willingness was measured on a 7-point scale with 0 = not likely, 6 = very 
likely. For the purpose of this study, the construct of willingness to request a pharmaceutical 
product was measured using a 7-point scale ranging from 1 = very unlikely, 7 = very likely.  
The hypothesized relationships among these variables and statistical designations are presented in 
Figure 2 and Figure 3. Data were analyzed using the PROCESS macro in SPSS v23 (Hayes 
2013). 
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c’ 
Figure 2: Conceptual and Statistical Diagram of Single Mediator Model for Effects of 
Fluency on Familiarity and Perceived Risk 
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Analysis 
The data analysis plan for the first two specified aims of the study is discussed below. 
 
Aim 1. Evaluate the perceived risk associated with a pharmaceutical brand name based on 
the pharmaceutical brand name fluency. 
Illustration of the direct effect of fluency on perceived risk 
Perceived Risk 
Illustration of single mediation design of fluency to exert 
an indirect effect on perceived risk through familiarity 
Fluency Perceived Risk 
Fluency 
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Aim 2. Investigate whether the effects of pharmaceutical brand name fluency on perceived 
risk is mediated by familiarity. 
 
To address the first two aims of the study and test the corresponding hypotheses, a two- 
condition between-subject approach was used for testing statistical significance of the single 
mediation model. Using the two-condition between-subject design, three linear equations were 
used to estimate the components of the hypothesized single-mediator model (MacKinnon 2008; 
Montoya and Hayes 2015). The first step was to regress perceived risk 
(Y) on pharmaceutical brand name fluency (X) and is used to assess the main effect of fluency on 
perceived risk (equation 1). 
Y = 1 + cX + 1 (1) 
Consistent with the single mediation model presented in Figure 2, Y represents the 
dependent variable of perceived risk, X represents the independent variable of pharmaceutical 
brand name fluency, c represents the relationship between pharmaceutical brand name fluency 
and perceived risk, 1 represents the intercepts, and 1 is the unexplained or error variance 
(MacKinnon 2008). This equation defines the total effect model and c, the parameter estimate, 
represents the effect of fluency on perceived risk. 
Even if the relationship between these two variables is found to be statistically significant, 
a mediated effect may still be present. Following the recommendations by MacKinnon (2008), 
the following two regression equations are then analyzed and assessed for mediation: 
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Y = 2 + c’X + bM + 2 (2) 
 
 
M = 3 + aX +3 (3) 
 
Consistent with the model presented in Figure 2, c’ represents the strength of prediction of 
perceived risk from fluency, with the strength of the relationship between familiarity and 
perceived risk removed (MacKinnon 2008; MacKinnon and Fairchild 2010). Next, the notation b 
represents the coefficient for the strength of the relationship between familiarity and perceived 
risk with the strength of the relationship between fluency and perceived risk removed. Finally, 
the notation of a represents the coefficient for the strength of the relationship between fluency and 
familiarity. The intercepts for each equation, representing the average score for each variable are 
represented by 1-3 and the error terms are represented by 1-3 (MacKinnon 2008; MacKinnon 
and Fairchild 2009). 
To evaluate the hypothesized mediation effect, the bootstrap resampling method was used 
(Bollen and Stine 1992; Efron 1992,1988; MacKinnon 2008). This statistical approach to 
estimating and testing mediation effects has been shown to perform better than the Baron and 
Kenny (1986) approach in small sample size studies (20-80) such as this study (Zhang and Wang 
2007). 
The bootstrapping method has no distributional assumption on the indirect effect of ab 
from Figure 2. Instead, this method approximates the distribution using its bootstrap distribution 
(Zhang and Wang 2007). Using the original data set as a population, a bootstrap sample of N 
subjects with paired Y, X, and M randomly with replacement from the original data set was 
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obtained. Next, from this bootstrap sample, estimates of ab (a_b_) through the OLS method were 
obtained based on the second and third equation previously listed. Both c and c’ from Figure 2 
are parameters relating fluency to perceived risk, but c’ is a partial effect, adjusted for the effects 
of familiarity (MacKinnon 2008). The estimate of the mediated effect is considered equal to ĉ –c.’.  
Repeating these first two steps, the empirical distribution of a_b_ based on the bootstrap 
procedure can be viewed as the distribution of ab. Then (1-) x 100% confidence interval of ab 
can be constructed using the (/2) x 100% and (1-/2) x 100% of the empirical distribution. 
Accordingly, if mediation effects have occurred, the indirect effect ab should be significantly 
different from zero (Zhang and Wang 2007; MacKinnon 2008). 
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CHAPTER IV: RESULTS 
 
The data analysis plan for the remaining two specified aims of the study is discussed 
below. 
 
Aim 3. Assess the effects of linguistic fluency and risk perception associated with 
pharmaceutical brand name fluency on a patient’s willingness to request the product. 
 
Aim 4. Assess whether disease severity moderates the relationship between perceived risk 
and patients’ willingness to request a pharmaceutical product 
 
To address the third and fourth aim of the study and test the statistical significance of the 
moderated serial mediator model, the statistical model is represented with the following three 
equations: 
 
M1 = iM1 + a1X + eM1 (4) 
 
 
M2 = iM2 + a2X + d1M1 + eM2 (5) Y = iy + c1’X + b1M1 + b2M2 
+ c2M2W + eY (6) 
 
  
36  
 
The serial mediator model has three specific indirect effects and one direct effect (Hayes 
2013). One pathway is indirect and runs from fluency to willingness to request through 
familiarity only. A second indirect path runs from fluency to willingness to request through 
perceived risk only. A third indirect influence passes through both familiarity and perceived risk 
sequentially, with familiarity affecting perceived risk (Hayes 2013). The remaining effect of 
fluency is direct to willingness to request without passing through either familiarity or perceived 
risk (Hayes 2013). 
The three indirect effects are estimated as the product of regression weights linking fluency 
to willingness to request through at least one mediator, familiarity or perceived risk (Hayes 2013). 
The specific indirect effect of fluency on willingness to request through familiarity only is 
represented as a1b1, the specific indirect effect through perceived risk only is represented as a2b2, 
and the specific indirect effect through both familiarity and perceived risk in serial is a1d21b2. 
(Hayes 2013). Combining these three indirect effects sum to the total indirect effect of fluency, 
represented as a1b1 + a2b2 + a1d21b2 (Hayes 2013). When the   total indirect effect of fluency is 
added to the direct effect of fluency, the result is c, which is the total effect of fluency, and can be 
estimated from the following regression equation: 
 
c = c’ + a1b1 + a2b2 + a1d11b2 (7) 
  
The total indirect effect of fluency on willingness to request in the serial mediator model 
is the difference between the total effect of fluency on willingness to request and the direct effect 
of fluency on willingness to request, as represented by the following equation: 
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c - c’ = a1b1 + a2b2 + a1d11b2 (8) 
Similar to the bootstrapping procedure described previously, bootstrap confidence 
intervals for indirect effects were calculated repeatedly resampling from the data with 
replacement, estimating the model in each bootstrap sample, calculating the indirect effects 
described, and deriving endpoints of confidence intervals for each (Hayes 2013). An indirect 
effect can be determined different from zero when the confidence interval does not contain zero 
(Hayes 2013). 
An analysis of the manipulation check indicated that the ten disfluent drug names were 
considered more difficult to pronounce compared to the ten fluent drug names (t = 5.612, 
p<0.001). Rankings for each of the ten drug names for both fluent and disfluent groups are 
provided in table 1. 
 
Table 1: Fluency Ratings for Pharmaceutical Brand Names 
 
 
 
Velcin 6.07 1.181 Quthutix 2.65 1.780 
Trivete 5.48 1.346 Niyxob 2.83 1.579 
Naxalon 5.46 1.486 Oxgnue 3.21 1.864 
Altorex 5.43 1.455 Vetlixfi 3.50 1.924 
Cutrino 4.98 1.832 Asbixat 3.54 1.890 
Runfina 4.63 1.743 Enyvfo 3.65 1.940 
Vithoria 4.57 1.940 Subridke 3.69 1.858 
Solotho 4.43 1.747 Qxibinle 3.75 1.707 
Evafir 4.39 1.612 Docilge 4.17 1.730 
Solatu 4.13 1.655 Oxtieze 4.23 1.574 
Interval response scale ranging from 1 = very difficult to pronounce, 7 = easy to pronounce 
A total of 94 participants with a self-reported diagnosis of rheumatoid arthritis completed the 
Fluent Group Disfluent Group 
Drug Name 
Mean Fluency 
Rating 
Std. Dev. Drug Name 
Mean Fluency 
Rating 
Std. Dev. 
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study (94% response rate). Participants averaged 52 years in age, with most being female (82%) 
and Caucasian (65%). Of the 94 participants who completed the study, 95% were native English 
speaking, and no participant indicated that they worked in a healthcare related field or for a 
healthcare organization. More than half of the participants (57%) reporting taking four or more 
prescription medications, and 82% indicated taking at least one prescription medication 
specifically for their rheumatoid arthritis. An overview of study participant demographics and 
sample characteristics is provided in table 2. 
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Table 2: Study Participant Demographics and Sample Characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Median VAS score 
Demographic Characteristic Total Fluent names Disfluent names 
Age, years 52.7 (29-71) 53.2 (29-69) 52.3 (31-71) 
Sex    
Male 17 (18%) 7 (15%) 10 (21%) 
Female 77 (82%) 39 (85%) 38 (79%) 
Ethnicity    
White 61 (65%) 32 (70%) 29 (60%) 
Hispanic or Latino 9 (10%) 3 (7%) 6 (13%) 
Black or African American 21 (22%) 11 (24%) 10 (21%) 
Native American or American Indian 0 (0%) 0 (0%) 0 (0%) 
Asian/Pacific Islander 1 (1%) 0 (0%) 1 (2%) 
Other 2 (2%) 0 (0%) 2 (4%) 
Native English (US) speaker    
Yes 89 (95%) 44 (96%) 45 (94%) 
No 5 (5%) 2 (4%) 3 (6%) 
Highest degree or level of school    
High school or diploma equivalent (e.g., GED) 25 (27%) 7 (15%) 18 (38%) 
Associate degree 33 (35%) 17 (37%) 16 (33%) 
Bachelor’s degree 28 (30%) 17 (37%) 11 (23%) 
Master’s degree 7 (7%) 4 (9%) 3 (6%) 
Professional degree 1 (1%) 1 (2%) 0 (0%) 
Doctorate degree 0 (0%) 0 (0%) 0 (0%) 
Work in healthcare related field    
Yes 0 (0%) 0 (0%) 0 (0%) 
No 94 (100%) 46 (100%) 48 (100%) 
Total number of prescriptions    
None 5 (5%) 1 (2%) 4 (8%) 
1-3 prescriptions 36 (38%) 23 (50%) 13 (27%) 
4-6 prescriptions 30 (32%) 12 (26%) 18 (38%) 
More than 6 prescriptions 23 (25%) 10 (22%) 13 (27%) 
Number of RA prescriptions    
None 17 (18%) 9 (20%) 8 (17%) 
1 32 (34%) 17 (37%) 15 (31%) 
2 28 (30%) 15 (33%) 13 (27%) 
3 or more 17 (18%) 5 (11%) 12 (25%) 
Type of RA medication    
Injected or infused 9 (10%) 6 (13%) 3 (6%) 
Oral 40 (43%) 19 (41%) 21 (44%) 
Both injected or infused and oral 28 (30%) 12 (26%) 16 (33%) 
Not sure 0 (0%) (0%) (0%) 
Disease severity    
Pain score* 51.50* 42.00* 61.00* 
Health score* 40.00* 30.50* 50.00* 
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The first and second hypotheses stated that there is a statistically significant relationship between 
the fluency of individual pharmaceutical brand names and patients’ perceived risk of the 
pharmaceutical product and that the relationship between linguistic fluency of pharmaceutical 
brand names and perceived risk is mediated by familiarity. As indicated in Table 3, results from a 
single mediation analysis showed that participants exposed to fluent brand names did not 
consider the products to be more familiar (a = 2.604, p = 0.237); however, participants who 
considered the brand names to be familiar did consider perceived risk to be lower (b = 0.221, p = 
0.006). A bias-corrected bootstrap confidence interval for the indirect effect (ab = 0.575) based 
on 10,000 bootstrap samples was not found to be significant (-0.239, 1.808). Furthermore, there 
was no evidence that the fluency of the brand names influenced the perceived risk of the product 
independent of the effects of fluency on familiarity (c’ = 1.293, p = 0.434). 
 
 
 
Table 3: Regression Coefficients, Standard Errors, and Model Summary for 
Single Mediation Model for Effects of Brand Name Fluency on Perceived 
Risk 
 
 
 
 
Variable 
  
Coeff. 
 
SE 
 
P 
  
Coeff. 
 
SE 
 
P 
Fluency (X) a 2.604 2.187 0.237 c’ 1.293 1.644 0.434 
Familiarity (M)  --- --- --- b 0.221 0.078 0.006 
Constant i1 16.00 1.563 <.001 i2 36.618 1.705 <.001 
 
 
R2 = 0.015 R2 = 0.093 
 
 
F (1,92) = 1.4185, p = 0.237 F (2,91) = 4.689, p = 0.012 
 
 
 
 
 
 
Familiarity (M) Perceived Risk (Y) 
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Figure 4: Statistical Diagram of Single Mediation Model for Effects of Brand 
Name Fluency on Perceived Risk 
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Next, a serial mediation model with a second-stage moderating variable was analyzed to 
assess the third and fourth hypotheses. The estimated regression coefficients from the serial 
mediation model are presented in Table 4. Brand name fluency did not affect familiarity of the 
product (a1 = 2.604, p = 0.237) or the perceived risk of the product (a2 = 1.293, p = 0.434). Like 
findings from the single mediation analysis, perceived risk of the pharmaceutical product is 
associated with the familiarity of the brand name (d1 = 0.221, p = 0.006); however, willingness 
to request the pharmaceutical product is not affected by the perceived risk of the product (b2 = 
0.364, p = 0.423), regardless of the level of disease severity (b3 = 0.003, p = 0.382). 
The first indirect effect assessing the indirect effect of brand name fluency on willingness 
Fluency Perceived Risk 
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to request the product through familiarity, estimated as a1b1, was not found to be significant 
(a1b1 = 0.336, -0.336, 1.452). The second indirect effect assessing the effect of brand name 
fluency on willingness to request the product through both familiarity and perceived risk, 
estimated as a1d1b2, was also found to not be significant (a1d1b2 = 0.209, -0.463, 1.084). 
Finally, the third indirect effect of brand name fluency on willingness to request the product 
through perceived risk, estimated as a2b2 was found to not be significant (a2b2 = 0.471, - 0.829, 
3.611). The total indirect effect estimating the sum of all three indirect effects was determined to 
not be different from zero (1.017, -0.795, 4.908). 
Using PROCESS (Hayes 2013), all possible pairwise comparisons between the three 
specified indirect effects are calculated to inform inference about differences between the specific 
indirect effects. The confidence intervals for the three contrasts ([C1 = -0.837, 1.359], [C2 = -
3.288, 1.639], and [C3 = -3.156, 1.218]) include zero and are not statistically different from each 
other. 
  
 
4
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Table 4: Regression Coefficients, Standard Errors, and Model Summary for Serial Mediation Model for Effects of 
Brand Name Fluency on Willingness to Request 
 
 
 
 
 
Fluency (X) a1 2.604 -1.738, 6.947 a2 1.293 -1.972, 4.559 c’ 1.158 -3.966, 6.281 
 
 
Familiarity 
(M1) 
Perceived Risk 
(M2) 
Disease 
Severity (W) 
M2 x W 
--- --- d1 0.221 0.066, 0.375 b1 0.129 -0.125, 0.383 
 
-0.535, 1.253 
 
--- 
 
-0.004, 0.010 
 
 
Constant iM1 16.000 12.897, 19.103 iM2 36.618 33.230, 40.005 iY 18.695 -18.159, 55.549 
 
 
 
 
R2 = 0.15 
 
F (1,92) = 1.4185, p = 0.237 
R2 = 0.093 
 
F (2,91) = 4.689, p = 0.012 
R2 = 0.274 
 
F (5,88) = 6.632, p = <0.001 
 
 
 
 
 
 
 
 
 
 
 
Familiarity (M1) Perceived Risk (M2) Willingness to Request (Y) 
Coeff. 95% CI 
Coeff. 
95% CI Coeff. 95% CI 
 
--- 
 
--- 
 
--- 
 
--- 
 
b2 
 
0.364 
 
--- 
 
--- 
 
--- 
 
--- 
  
--- 
--- --- --- --- b3 0.003 
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Figure 5: Statistical Diagram of Serial Mediation Model 
for Effects of Brand Name Fluency on 
Willingness to Request 
 
 
 
em1 em2 
 
  
d1 = 0.221 
 
 
b3 = 0.003 
 
 
 
a
1 
= 
2
.
6
0
4 
 
 
a2 = 1.293 
 
b1 = 0 
129 
 
ey 
b2 = 0.364 
 
 
c’ = 1.158 
 
 
 
 
 
 
 
 
 
Sensitivity analyses 
Following formal testing of the four study hypotheses, sensitivity analyses were conducted 
to assess sensitivity of key study measures across varied settings. First, the original single 
mediation model assessing the relationship between fluency of individual pharmaceutical brand 
names and patients’ perceived risk of the pharmaceutical product and whether the relationship 
between linguistic fluency of pharmaceutical brand names and perceived risk is mediated by 
familiarity was analyzed. The difference in the sensitivity analyses and the original hypothesis 
Fluency 
Familiarity Perceived Risk 
WTR 
Disease 
Severity 
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testing for the first two study hypotheses included three different settings for the study measures. 
In the first sensitivity analysis, perceived novelty instead of familiarity was analyzed to 
determine if novelty mediated the relationship between pharmaceutical brand name fluency and 
perceived risk. As can be seen in table 5, results from a single mediation analysis showed that 
participants exposed to fluent brand names did not consider the products to be more novel (a = 
3.788, p = 0.099) and novelty did not influence perceived risk (b = 0.150, p = 0.052). A bias-
corrected bootstrap confidence interval for the indirect effect (ab = 0.568) based on 10,000 
bootstrap samples was not found to be significant (-0.01, 2.066). Furthermore, there was no 
evidence that the fluency of the brand names influenced the perceived risk of the product 
independent of the effects of fluency on familiarity (c’ = 1.300, p = 0.445). 
 
 
Table 5: Regression Coefficients, Standard Errors, and Model Summary for 
Single Mediation Model for Effects of Brand Name Fluency on Perceived 
Risk (Sensitivity Analysis with Novelty as Mediator) 
 
 
 
 
 
Variable 
  
Coeff. 
 
SE 
 
P 
  
Coeff. 
 
SE 
 
P 
Fluency (X) a 3.788 2.276 0.099 c’ 1.299 1.692 0.445 
Novelty (M)  --- --- --- b 0.150 0.076 0.052 
Constant i1 45.587 1.626 <0.001 i2 33.299 3.680 <0.001 
 
 
R2 = 0.029 R2 = 0.053 
 
 
F (1,92) = 2.771, p = 0.099 F (2,91) = 2.566, p = 0.082 
 
 
 
 
 
In the second post-hoc analysis, the three study variables included in the single mediation 
analysis were only assessed based on the first pharmaceutical brand name presented to the 
participant, as opposed to each participate evaluating all ten brand names within the randomized 
Novelty (M) Perceived Risk (Y) 
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group assignment.  As seen in table 6, results from a single mediation analysis using responses 
from the first brand name presented only showed that the participants exposed to the first fluent 
brand name only did not consider the products to be more familiar (a = 0.157, p = 0.379) and 
familiarity was not associated with the perceived risk of the product (b = 0.244, p = 0.064). A 
bias-corrected bootstrap confidence interval for the indirect effect (ab = 0.38) based on 10,000 
bootstrap samples was not found to be significant (-0.029, 0.193). Furthermore, there was no 
evidence that the fluency of the brand names influenced the perceived risk of the product 
independent of the effects of fluency on familiarity (c’ = -0.025, p = 0.912). 
 
 
Table 6: Regression Coefficients, Standard Errors, and Model Summary for 
Single Mediation Model for Effects of Brand Name Fluency on Perceived 
Risk (Sensitivity Analysis with First Name) 
 
 
 
Variable 
  
Coeff. 
 
SE 
 
P 
  
Coeff. 
 
SE 
 
P 
Fluency (X) a 0.157 0.177 0.379 c’ -0.025 0.221 0.912 
Familiarity (M)  --- --- --- b 0.244 0.130 0.064 
Constant i1 1.239 0.127 <0.001 i2 3.872 0.225 <0.001 
 
 
R2 = 0.008 R2 = 0.037 
 
 
F (1,92) = 0.782, p = 0.379 F (2,91) = 1.764, p = 0.177 
 
 
 
 
Finally, in the third sensitivity analysis, the three study variables included in the single 
mediation analysis were only assessed based on the either the most fluent or disfluent 
pharmaceutical brand name presented to the participant, as opposed to each participate evaluating 
all ten brand names within the randomized group assignment. As seen in table 7, results from a 
single mediation analysis using responses from the most fluent or most disfluent brand name 
presented only showed that fluency was not associated with familiarity (a = 0.456, p = 0.122) 
Familiarity (M) Perceived Risk (Y) 
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and familiarity was not associated with the perceived risk of the product (b = 0.093, p = 0.234). A 
bias-corrected bootstrap confidence interval for the indirect effect (ab = 0.042) based on 10,000 
bootstrap samples was not found to be significant (-0.011, 0.200). Furthermore, there was no 
evidence that the fluency of the brand names influenced the perceived risk of the product 
independent of the effects of fluency on familiarity (c’ = 0.228, p = 0.305). 
 
 
Table 7: Regression Coefficients, Standard Errors, and Model Summary for 
Single Mediation Model for Effects of Brand Name Fluency on Perceived 
Risk (Sensitivity Analysis with Most Fluent and Disfluent Name) 
 
 
 
Variable 
  
Coeff. 
 
SE 
 
P 
  
Coeff. 
 
SE 
 
P 
Fluency (X) a 0.456 0.292 0.122 c’ 0.228 0.221 0.305 
Familiarity (M)  --- --- --- b 0.093 0.078 0.234 
Constant i1 1.565 0.209 <0.001 i2 3.877 0.198 <0.001 
 
 
R2 = 0.026 R2 = 0.032 
 
 
F (1,92) = 2.434, p = 0.122 F (2,91) = 1.485, p = 0.232 
 
 
 
 
 
Using the same post-hoc variables as analyzed in the single mediation models, we then 
assessed the variables in the serial mediation model to determine sensitivity in key study 
measures within the full model. First, perceived novelty instead of familiarity was analyzed as 
the first mediating variable in the serial mediation model. The first indirect effect assessing the 
indirect effect of brand name fluency on willingness to request the product through novelty, 
estimated as a1b1, was not found to be significant (a1b1 = 0.515, -0.939, 1.936). The second 
indirect effect assessing the effect of brand name fluency on willingness to request the product 
through both novelty and perceived risk, estimated as a1d1b2, was also found to not be 
Familiarity (M) Perceived Risk (Y) 
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significant (a1d1b2 = 0.205, -0.383, 1.082). Finally, the third indirect effect of brand name 
fluency on willingness to request the product through perceived risk, estimated as a2b2 was 
found to not be significant (a2b2 = 0.468, -0.861, 4.050). The total indirect effect estimating the 
sum of all three indirect effects was determined to not different from zero (1.187, -1.068, 5.465). 
The estimated regression coefficients from the serial mediation model are presented in Table 8. 
  
4
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Table 8: Regression Coefficients, Standard Errors, and Model Summary for Serial Mediation Model for Effects of 
Brand Name Fluency on Willingness to Request (Sensitivity Analysis with Novelty) 
 
 
 
 
 
Fluency (X) a1 3.788 -0.732, 8.308 a2 0.150 -0.001, 0.302 c’ 0.853 -4.296, 6.002 
 
Novelty (M1) --- --- d1 0.150 -0.001, 0.302 b1 0.136 -0.095, 0.367 
Perceived 
---
 
Risk (M2) 
 
--- 
  
--- 
 
--- 
 
b2 
 
0.360 -0.537, 1.257 
Disease 
---
 
Severity (W) 
 
--- 
  
--- 
 
--- 
  
--- --- 
M2 x W --- ---  --- --- b3 0.003 -0.004, 0.010 
Constant iM1 16.000 12.897, 19.103 iM2 36.618 33.230, 40.005 iY 18.695 -18.159, 55.549 
 
 
R2 = 0.292 
 
F (1,92) = 2.771, p = 0.099 
R2 = 0.053 
 
F (2,91) = 2.566, p = 0.082 
R2 = 0.277 
 
F (5,88) = 6.726, p = <0.001 
Novelty (M1) Perceived Risk (M2) Willingness to Request (Y) 
Coeff. 95% CI 
Coeff. 
95% CI Coeff. 95% CI 
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Next, the three main study variables (fluency, familiarity, and perceived risk) included in 
the single mediation analysis were only assessed based on the first pharmaceutical brand name 
presented to the participant, as opposed to each participate evaluating all ten brand names within 
the randomized group assignment. The first indirect effect assessing the indirect effect of brand 
name fluency on willingness to request the product through familiarity, estimated as a1b1, was 
not found to be significant (a1b1 = 0.121, -0.049, 0.068). The second indirect effect assessing the 
effect of brand name fluency on willingness to request the product through both familiarity and 
perceived risk, estimated as a1d1b2, was also found to not be significant (a1d1b2 = 0.007, -
0.026, 0.054). Finally, the third indirect effect of brand name fluency on willingness to request 
the product through perceived risk, estimated as  a2b2 was found to not be significant (a2b2 = -
0.004, -0.138, 0.184). The total indirect effect estimating the sum of all three indirect effects was 
determined to not different from zero (0.015, -0.143, 0.219). The estimated regression 
coefficients from the serial mediation model are presented in Table 9. 
 Finally, the three main study variables (fluency, familiarity, and perceived risk) were only 
assessed for the brand name considered most fluent (i.e., easiest to pronounce) and the brand 
name considered the most disfluent (i.e., hardest to pronounce). 
 The first indirect effect assessing brand name fluency on willingness to request the 
product through familiarity, estimated as a1b1, was not found to be significant (a1b1 = 0.063, -
0.024, 0.225). The second indirect effect assessing the effect of brand name fluency on 
willingness to request the product through both familiarity and perceived risk, estimated as 
a1d1b2, was also found to not be significant (a1d1b2 = 0.019, -0.046, 0.081). The third indirect 
effect of brand name fluency on willingness to request the product through perceived risk, 
estimated as a2b2 was found to not be significant (a2b2 = -0.100, 0.088, 0.501). The total indirect 
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was determined to not different from zero (0.182, -0.049, 0.613). The estimated regression 
coefficients from the serial mediation model are presented in Table 10. 
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Table 9: Regression Coefficients, Standard Errors, and Model Summary for Serial Mediation Model for Effects of Brand 
Name Fluency on Willingness to Request (Sensitivity Analysis with First Name) 
 
 
 
 
 
Fluency (X) a1 0.456 -0.124, 1.036 a2 0.228 -0.211, 0.666 c’ 0.107 -0.439, 0.652 
 
 
Familiarity 
(M1) 
Perceived Risk 
(M2) 
Disease 
Severity (W) 
M2 x W 
Constant 
-0.049, 0.327 
 
-0.338, 1.220 
 
--- 
 
-0.004, 0.008 
-1.682, 4.821 
 
 
 
 
R2 = 0.026 
 
F (1,92) = 2.434, p = 0.122 
R2 = 0.032 
 
F (2,91) = 1.484, p = 0.232 
R2 = 0.315 
 
F (5,88) = 8.092, p = <0.001 
 
 
Familiarity (M1) Perceived Risk (M2) Willingness to Request (Y) 
Coeff. 95% CI 
Coeff. 
95% CI Coeff. 95% CI 
  
--- 
 
--- d1 0.093 -0.061, 0.247 b1 0.139 
 
--- 
 
--- 
  
--- 
 
--- 
 
b2 
 
0.441 
 
--- 
 
--- 
  
--- 
 
--- 
  
--- 
--- ---  --- --- b3 0.002 
iM1 1.565 1.151, 1.980 iM2 3.876 3.484, 4.268 iY 1.569 
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Table 10: Regression Coefficients, Standard Errors, and Model Summary for Serial Mediation Model for Effects of Brand 
Name Fluency on Willingness to Request (Sensitivity Analysis with Most Fluent and Disfluent Name) 
 
 
 
 
 
Fluency (X) a1 0.157 -0.195, 0.509 a2 0.150 -0.001, 0.302 c’ 0.244 -0.323, 0.811 
 
 
Familiarity 
(M1) 
Perceived Risk 
(M2) 
Disease 
Severity (W) 
M2 x W 
--- --- d1 0.244 -0.014, 0.501 b1 0.077 -0.253, 0.407 
 
-0.473, 0.824 
 
--- 
 
-0.001, 0.010 
 
 
Constant iM1 16.000 12.897, 19.103 iM2 36.618 33.230, 40.005 iY 18.695 -18.159, 55.549 
 
 
 
 
R2 = 0.008 
 
F (1,92) = 0.782, p = 379 
R2 = 0.037 
 
F (2,91) = 1.764, p = 0.177 
R2 = 0.288 
 
F (5,88) = 7.121, p = <0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Familiarity (M1) Perceived Risk (M2) Willingness to Request (Y) 
Coeff. 95% CI 
Coeff. 
95% CI Coeff. 95% CI 
 
--- 
 
--- 
 
--- 
 
--- 
 
b2 
 
0.176 
 
--- 
 
--- 
 
--- 
 
--- 
  
--- 
--- --- --- --- b3 0.004 
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CHAPTER V: DISCUSSION 
 
The current research is the first study to our knowledge that demonstrates pharmaceutical 
brand name fluency does not affect perceived risk of the product or willingness to request the 
medication in actual patients who are evaluating drug names indicated to treat their condition or 
disease. In a study among participants with rheumatoid arthritis, we did not find evidence that the 
difficulty of pharmaceutical brand names affected evaluations of the product’s perceived risk or 
willingness to request the medication from a prescribing physician, even for patients with more 
advanced disease. Furthermore, and contrary to most previous fluency theory research with drug 
names, the perceived familiarity, or newness of the product, was not associated with the fluency 
of the pharmaceutical brand name. Our findings do align with recent research by Dohle and 
Montoya (2017) in which the researchers demonstrated that fluent drug names resulted in a 
positive as opposed to a negative affective response, which reduced the perceived risks of the 
drugs. Dohle and Montoya (2017) also did not find evidence to support the mediating role of 
familiarity between the fluency-risk relationship. Additionally, recent work by Bahnik and 
Vranka (2017) reported that the relationship between fluency and perceived risk may be much 
less robust or even nonexistent. Through a series of experiments, the researchers concluded that 
the association between fluency and perceived safety was explained by the length of the name 
being evaluated by participants (Bahnik and Vranka 2017). Thus, although findings from the 
current study contradict much of the previous fluency theory research involving brand names, 
particularly in the context of drug names, recent studies have brought into question the robustness 
 55  
and generalizability of the association between processing fluency and judgements of risk. 
Two important distinctions between this research and previous fluency theory research 
involving drug names are worth noting. First, this is the first study we are aware of that used 
study participants who have direct experience with pharmaceuticals in general, and more 
specifically, pharmaceuticals indicated to treat a specific condition in which participants are 
known to have. Previous fluency theory research involving drug names have not been conducted 
with patients in a specific condition or category. This is important difference as actual patients 
may be more conditioned to evaluating pharmaceutical brand names and rely upon surrogate 
decision makers (i.e., FDA, prescribing physicians) to make trade-off decisions between safety 
and efficacy. Research conducted thus far has primarily included students as study participants. 
Evaluating brand names, and drug names, from the perspective of a student differs considerably 
from that of a patient evaluating the brand names of product indicated to treat a condition for 
which the patient has been diagnosed. 
 Treatment naïve individuals may inherently be more likely to consider risk associated with 
a product as a result of less experience with pharmacologic treatments. Experienced patients may 
become conditioned through direct experience with pharmacologic therapy and the side effects 
associated with treatment. Although Schwarz (2004) demonstrated that the metacognitive 
experiences of general consumers are guided by processing fluency, the process may differ in the 
context of healthcare. General consumers are much less informed and experienced with drug 
therapy and may be more susceptive to the effects of processing fluency for pharmaceutical 
products. In fact, Dohle and Siegrist (2014) acknowledged that in a real-world setting, people 
actually afflicted by a condition may react differently to heuristic cues such as the complexity of 
a brand name. 
 56  
Second, contrasting previous research, this study incorporated a between-subjects design 
in which participants were randomly assigned to either an easy-to-pronounce group of 
pharmaceutical brand names or a hard-to-pronounce group of pharmaceutical brand names. 
Extant literature (Song and Schwartz, 2009; Dohle and Siegrist, 2014; Tasso, Gavaruzzi, and 
Lotto, 2014; Cho, 2015; Dohle and Montoya, 2017) incorporated within-subjects designs in 
studies, exposing participants to both conditions of fluency. Methodological considerations, both 
disadvantages and advantages between the two experimental design approaches, have received 
considerable attention in the economic and psychology literature (Charness, Uri, and Kuhn, 
2012). One particular risk associated with a within-subjects design is a “demand effect”, in which 
study participants either consciously or subconsciously attempt to interpret the intentions of the 
experiment and change their behavior accordingly (Charness, Uri, and Kuhn, 2012). As a result 
of considerations for the strengths and limitations of the two experimental design methods, 
between-subject designs have been considered to result in higher external validity in situations in 
which an individual is faced with a single decision, which is often the case in evaluations of 
whether a patient is willing to request a medication from his/her prescribing physician based on 
an advertisement for the medication as evaluated within the current study. 
To demonstrate differences in these two methodological approaches, Hayes and Montoya 
(2016) recently used the work by Dohle and Siegrist (2014) which, based on fluency theory, 
assessed perceived hazardous and willingness to buy drugs based on drug name. In a similar 
single mediation model as hypothesized here within the current research, Dohle and Siegrist 
(2014) assumed the effects of drug name fluency (i.e., complexity) would be mediated on 
willingness to buy through participants perceived hazardousness. Hayes and Montoya (2016) 
applied a hypothetical between-subjects approach to the Dohle and Siegrist (2014) data and found 
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that complex sounding names were considered to be more hazardous than drugs with simpler 
names (t [42] = 2.618, p = 0.012, 95% CI [0.183,1.417]) which negatively affected willingness to 
buy through hazardousness (Hayes and Montoya, 2016). However, the mediation analysis 
conducted by Dohle and Siegrist (2014) using the within-subjects design found no statistically 
significant difference in willingness    to buy based on drug name but instead, concluded a full or 
complete mediation effect, indicating that differences in hazardousness predicts willingness to 
buy (Hayes and Montoya, 2016). Disparate results from previous fluency theory research found 
within the current study may partially be the result of methodological advantages of the between- 
subjects design incorporated in this study. 
 
Limitations 
There are limitations associated with this research that should be recognized. Participants 
evaluated hypothetical brand names of products indicated to treat RA. Patients self- identified as 
having been previously diagnosed with RA and therefore a confirmed diagnosis was not obtained 
for study participants. Although the survey captured participants’ experience with various forms 
of RA treatment and their measure of disease severity, it is possible that participants did not have 
a confirmed clinical diagnosis of RA and therefore may not be suited to evaluate hypothetical 
products indicated to treat RA. Additionally, although the study incorporated a between-subjects 
designs, participants in each fluency group were exposed to a total of 10 brand names and could 
have experienced response burden or responder fatigue as a result. A sensitivity analysis was 
conducted to address this limitation by only analyzing the first brand name presented to each 
respondent. Finally, although this study attempts to investigate the fluency risk connection in a 
real-world setting with patients, the findings may not translate to other conditions outside of RA. 
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Patients with conditions that differ in symptoms, criticality, and even prevalence from that of RA 
may respond dissimilarly when evaluating brand names indicated to treat their disease. 
 
Implications 
The current study has implications for both the growing body of fluency theory research 
and pharmaceutical industry itself. First, this study provides additional evidence as to the 
potential limitations in the previously established link between processing fluency and 
judgements such as perceived risk. Although the original work by Song and Schwartz (2009) has 
been replicated in subsequent studies, recent work by Dohle and Siegrist (2014), Bahnik and 
Vranka (2017), and the current study have demonstrated conflicting results     to the relationships 
between processing fluency and judgements associated with disfluent brand names. 
Future research should explore these possible boundary conditions and assess the 
robustness and generalizability of the fluency risk relationship. From an industry perspective, the 
results are supportive of recent naming trends and indicate that the complexity of pharmaceutical 
brand names do not negatively influence patients’ willingness to act to advertising initiatives and 
request a medication from their healthcare provider. As the pharmaceutical market in the US 
continues to grow, with forty-six new products introduced in 2017 alone, pharmaceutical 
marketing practitioners should further investigate other judgements such as perceived efficacy 
and value that may be influenced by the complexity of the brand name. 
Additionally, it is important to understand the potential impact of the fluency risk 
relationship on prescribing practitioners. Physicians and health care providers act as surrogate 
consumers for patients in the US health care market by choosing medications to prescribe for a 
patient. Determining what effect, if any, the fluency of pharmaceutical brand names on 
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prescribing practitioners is needed to further expand the real-world impact of processing fluency 
in the context of pharmaceuticals. 
 
Conclusion 
In conclusion, the present study suggests that ease of pronunciation of a pharmaceutical 
brand name does not affect patients perceived risk associated with the product or their willingness 
to request the medication from their healthcare provider. This research contributes to the fluency 
theory literature and provides a unique perspective on the real- world implications, or lack 
thereof, of brand name selection for pharmaceutical products. 
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Appendix A: Pre-test Instructions 
 
Thank you for your willingness to participate in this study. Your input is very valuable to the research team. 
 
Throughout this process, you will see a series of 45 brand names of pharmaceutical products. We are interested in 
how easy, or difficult, each of the brand names are to pronounce. The following scale will be used so that you can 
rate each brand name based on ease of pronunciation. You will have a chance to rate each individual brand name 
before going to the next product. 
 
NOTE: Each numerical value will have a check box function to allow participants to select (or click) the appropriate 
number. 
 
Please rate the following pharmaceutical brand names how easy the names are to pronounce. 
 
 
1 2 3 4 5 6 7 
 
 
Placed directly above each numerical value will be the following labels: 
 
1 = Very difficult to pronounce 
2 = Moderately difficult to pronounce 3 = 
Slightly difficult to pronounce 
4 = Neither easy nor difficult to pronounce 5 = 
Slightly easy to pronounce 
6 = Moderately easy to pronounce 7 = Very 
easy to pronounce 
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Appendix B: Example Study Measure Format 
 
 
 
 
 
 
 
Imagine you see the following pharmaceutical product name and 
accompanying information during an advertisement for the product. 
Rotipix 
Rotipix is a pharmaceutical product 
that is indicated for the treatment of 
Rheumatoid Arthritis 
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Perceived Familiarity 
 
How would you rate the novelty of the product brand name listed above? 
 
 
1 2 3 4 5 6 7 
 
 
Placed directly above each numerical value will be the following labels: 1 = Very old 
2 = Moderately old 3 = 
Slightly old 
4 = Neither old nor new 5 = 
Slightly new 
6 = Moderately new 7 = 
Very new 
 
 
 
Perceived Risk Measure 
 
How well do you expect the product listed above will perform? 
 
 
1 2 3 4 5 6 7 
 
 
Placed directly above each numerical value will be the following labels: 1 = Extremely 
poor 
2 = Moderately poor 3 = 
Slightly poor 
4 = Neither poor nor good 5 = 
Slightly good 
6 = Moderately good 7 = 
Extremely good 
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Perceived Risk Measure 
 
How concerned would you be about using the product listed above? 
 
 
1 2 3 4 5 6 7 
 
 
Placed directly above each numerical value will be the following labels: 1 = Consider the 
product very harmful 
2 = Consider the product moderately harmful 3 = 
Consider the product slightly harmful 
4 = Consider the product neither safe nor harmful 5 = Consider 
the product slightly safe 
6 = Consider the product moderately safe 7 = 
Consider the product very safe 
 
 
 
 
 
Willingness to Request 
 
 
1 2 3 4 5 6 7 
Placed directly above each numerical value will be the following labels: 1 = Very 
unlikely 
2 = Somewhat unlikely 3 = 
Unlikely 
4 = Neither unlikely nor likely 5 = 
Likely 
6 = Somewhat likely 7 = 
Very likely 
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Appendix C: Survey 
 
Q1 Investigator Contact 
 
David Wamble 
The University of Mississippi School of Pharmacy dewamble@go.olemiss.edu 
 
In this survey, you will be presented with a series of brand names for prescription pharmaceutical products 
indicated to treat rheumatoid arthritis. Once each product name is presented, you will be asked to respond to a few 
questions. Please select the most appropriate answer which best describes your impression of the pharmaceutical 
brand name. 
 
The survey will require approximately 10-15 minutes to complete. Participation is strictly voluntary and you may 
refuse to participate at any time. 
 
This study has been reviewed by The University of Mississippi’s Institutional Review Board (IRB). If you have 
any questions, concerns, or reports regarding your rights as a participant of research, please contact the IRB at 
(662) 915-7482 or irb@olemiss.edu. 
 
 
Statement of Consent 
 
I have read the procedure described above. Clicking the "Proceed" button below signifies that I voluntarily agree to 
participate in the survey. 
 
 
o Proceed 
o Do not proceed 
 
Q2 What is your age in years? 
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Q3 Have you ever been diagnosed with rheumatoid arthritis? 
 
o Yes 
o No 
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Q4 How long ago were you diagnosed with rheumatoid arthritis? 
 
o Less than 1 year ago 
o 1 to 3 years ago 
o 3 to 7 years ago 
o More than 7 years ago 
o Not sure 
 
Q5 What is your gender? 
 
o Male 
o Female 
 
Q6 Please specify your ethnicity 
 
o White 
o Hispanic or Latino 
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o Black or African American 
o Native American or American Indian 
o Asian/Pacific Islander 
o Other 
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Q7 Are you a native English (US) speaker? 
 
o Yes 
o No 
 
Q8 What is the highest degree or level of school you have completed? 
 
o High School or diploma equivalent (for example: GED) 
o Associate degree o 
Bachelor's degree o 
Master's degree  o 
Professional degree o 
Doctorate degree 
Q9 Do you work in a healthcare related field or for a healthcare organization? 
 
o Yes 
o No 
 
Q10 Approximately how many prescription medications are you currently taking? 
 
o None 
o 1 - 3 prescriptions 
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o 4 - 6 prescriptions 
o More than 6 prescriptions 
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Q11 Approximately how many prescription medications are you currently taking for rheumatoid arthritis? 
 
o None 
o 1 
o 2 
o 3 or more 
Q12 Are the medications you are currently taking for rheumatoid arthritis injected/infused or taken by mouth? 
 
o Injected/Infused 
o Oral 
o Both injected/infused and oral 
o Not sure 
Q13 How much pain have you had because of your rheumatoid arthritis IN THE PAST WEEK? On a scale of 0 to 
100 (where zero represents “no pain” and 100 represents “severe pain”), please slide the bar to record the number 
below. 
 
No pain Severe pain 
 
 
0 100 
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Q14 Considering all the ways that your arthritis affects you, please rate how well you are doing on a scale from 0 to 
100 (where zero represents “very well” and 100 represents “very poor” health). Please slide the bar to record the 
number below. 
 
Very well Very poor 
 
 
0 100 
 
 
 
 
 
 
Q15 You will now be presented with a series of brand names of prescription pharmaceutical products indicated to 
treat rheumatoid arthritis. Once each product name is presented, you will be asked to respond to a few questions. 
Please select the most appropriate answer which best describes your impression of the pharmaceutical brand name. 
 
 
Q16 
Imagine you see the following prescription pharmaceutical product name and accompanying information during an 
advertisement for the product 
 
Evafir 
 
Evafir is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid 
Arthritis 
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Q17 How familiar to you is the prescription pharmaceutical product listed above? 
 
o Very unfamiliar 
o Moderately unfamiliar 
o Slightly unfamiliar 
o Neither familiar nor unfamiliar 
o Slightly familiar o 
Moderately familiar o 
Very familiar 
Q18 How would you rate the novelty of the prescription pharmaceutical product listed above? 
 
o Very old 
o Moderately old 
o Slightly old 
o Neither old nor new 
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o Slightly new o 
Moderately new o 
Very new 
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Q19 How concerned would you be about using the prescription pharmaceutical product listed above? 
 
o Consider the product very harmful 
o Consider the product moderately harmful 
o Consider the product slightly harmful 
o Consider the product neither safe nor harmful 
o Consider the product slightly safe 
o Consider the product moderately safe 
o Consider the product very safe 
 
Q20 How willing would you be to request the prescription pharmaceutical product from your physician? 
 
o Very unlikely 
o Unlikely 
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o Somewhat unlikely 
o Neither unlikely nor likely 
o Somewhat likely 
o Likely 
o Very likely 
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Q21 
Imagine you see the following prescription pharmaceutical product name and accompanying information during an 
advertisement for the product 
 
Solotho 
 
Solotho is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid 
Arthritis 
 
 
 
Q22 How familiar to you is the prescription pharmaceutical product listed above? 
 
o Very unfamiliar 
o Moderately unfamiliar 
o Slightly unfamiliar 
o Neither familiar nor unfamiliar 
o Slightly familiar o 
Moderately familiar o 
Very familiar 
Q23 How would you rate the novelty of the prescription pharmaceutical product listed above? 
 
o Very old 
o Moderately old 
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o Slightly old 
o Neither old nor new 
o Slightly new o 
Moderately new o 
Very new 
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Q24 How concerned would you be about using the prescription pharmaceutical product listed above? 
 
o Consider the product very harmful 
o Consider the product moderately harmful 
o Consider the product slightly harmful 
o Consider the product neither safe nor harmful 
o Consider the product slightly safe 
o Consider the product moderately safe 
o Consider the product very safe 
 
Q25 How willing would you be to request the prescription pharmaceutical product from your physician? 
 
o Very unlikely 
o Unlikely 
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o Somewhat unlikely 
o Neither unlikely nor likely 
o Somewhat likely 
o Likely 
o Very likely Q26 
Imagine you see the following prescription pharmaceutical product name and accompanying information during an 
advertisement for the product 
 
Trivete 
 
Trivete is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid Arthritis 
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Q27 How familiar to you is the prescription pharmaceutical product listed above? 
 
o Very unfamiliar 
o Moderately unfamiliar 
o Slightly unfamiliar 
o Neither familiar nor unfamiliar 
o Slightly familiar o 
Moderately familiar o 
Very familiar 
Q28 How would you rate the novelty of the prescription pharmaceutical product listed above? 
 
o Very old 
o Moderately old 
o Slightly old 
o Neither old nor new 
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o Slightly new o 
Moderately new o 
Very new 
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Q29 How concerned would you be about using the prescription pharmaceutical product listed above? 
 
o Consider the product very harmful 
o Consider the product moderately harmful 
o Consider the product slightly harmful 
o Consider the product neither safe nor harmful 
o Consider the product slightly safe 
o Consider the product moderately safe 
o Consider the product very safe 
 
Q30 How willing would you be to request the prescription pharmaceutical product from your physician? 
 
o Very unlikely 
o Unlikely 
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o Somewhat unlikely 
o Neither unlikely nor likely 
o Somewhat likely 
o Likely 
o Very likely 
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Q31 
Imagine you see the following prescription pharmaceutical product name and accompanying information during an 
advertisement for the product 
 
Solatu 
 
Solatu is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid Arthritis 
 
 
 
Q32 How familiar to you is the prescription pharmaceutical product listed above? 
 
o Very unfamiliar 
o Moderately unfamiliar 
o Slightly unfamiliar 
o Neither familiar nor unfamiliar 
o Slightly familiar o 
Moderately familiar o 
Very familiar 
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Q33 How would you rate the novelty of the prescription pharmaceutical product listed above? 
 
o Very old 
o Moderately old 
o Slightly old 
o Neither old nor new 
o Slightly new o 
Moderately new o 
Very new 
Q34 How concerned would you be about using the prescription pharmaceutical product listed above? 
 
o Consider the product very harmful 
o Consider the product moderately harmful 
o Consider the product slightly harmful 
o Consider the product neither safe nor harmful 
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o Consider the product slightly safe 
o Consider the product moderately safe 
o Consider the product very safe 
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Q35 How willing would you be to request the prescription pharmaceutical product from your physician? 
 
o Very unlikely 
o Unlikely 
o Somewhat unlikely 
o Neither unlikely nor likely 
o Somewhat likely 
o Likely 
o Very likely Q36 
Imagine you see the following prescription pharmaceutical product name and accompanying information during an 
advertisement for the product 
 
Vithoria 
 
Vithoria is a prescription pharmaceutical product that is indicated for the treatment of 
Rheumatoid Arthritis 
 
 
Q37 How familiar to you is the prescription pharmaceutical product listed above? 
 
o Very unfamiliar 
o Moderately unfamiliar 
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o Slightly unfamiliar 
o Neither familiar nor unfamiliar 
o Slightly familiar o 
Moderately familiar o Very 
familiar 
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Q38 How would you rate the novelty of the prescription pharmaceutical product listed above? 
 
o Very old 
o Moderately old 
o Slightly old 
o Neither old nor new 
o Slightly new o 
Moderately new o Very new 
Q39 How concerned would you be about using the prescription pharmaceutical product listed above? 
 
o Consider the product very harmful 
o Consider the product moderately harmful 
o Consider the product slightly harmful 
o Consider the product neither safe nor harmful 
o Consider the product slightly safe 
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o Consider the product moderately safe 
o Consider the product very safe 
Q40 How willing would you be to request the prescription pharmaceutical product from your physician? 
 
o Very unlikely 
o Unlikely 
o Somewhat unlikely 
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o Neither unlikely nor likely 
o Somewhat likely 
o Likely 
o Very likely Q41 
Imagine you see the following prescription pharmaceutical product name and accompanying information during an 
advertisement for the product 
 
Runfina 
 
Runfina is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid 
Arthritis 
 
 
Q42 How familiar to you is the prescription pharmaceutical product listed above? 
 
o Very unfamiliar 
o Moderately unfamiliar 
o Slightly unfamiliar 
o Neither familiar nor unfamiliar 
o Slightly familiar o 
Moderately familiar o 
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Very familiar 
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Q43 How would you rate the novelty of the prescription pharmaceutical product listed above? 
 
o Very old 
o Moderately old 
o Slightly old 
o Neither old nor new 
o Slightly new o 
Moderately new o 
Very new 
Q44 How concerned would you be about using the prescription pharmaceutical product listed above? 
 
o Consider the product very harmful 
o Consider the product moderately harmful 
o Consider the product slightly harmful 
o Consider the product neither safe nor harmful 
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o Consider the product slightly safe 
o Consider the product moderately safe 
o Consider the product very safe 
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Q45 How willing would you be to request the prescription pharmaceutical product from your physician? 
 
o Very unlikely 
o Unlikely 
o Somewhat unlikely 
o Neither unlikely nor likely 
o Somewhat likely 
o Likely 
o Very likely Q46 
Imagine you see the following prescription pharmaceutical product name and accompanying information during an 
advertisement for the product 
 
Cutrino 
 
Cutrino is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid Arthritis 
 
 
Q47 How familiar to you is the prescription pharmaceutical product listed above? 
 
o Very unfamiliar 
o Moderately unfamiliar 
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o Slightly unfamiliar 
o Neither familiar nor unfamiliar 
o Slightly familiar o 
Moderately familiar o Very 
familiar 
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Q48 How would you rate the novelty of the prescription pharmaceutical product listed above? 
 
o Very old 
o Moderately old 
o Slightly old 
o Neither old nor new 
o Slightly new o 
Moderately new o 
Very new 
Q49 How concerned would you be about using the prescription pharmaceutical product listed above? 
 
o Consider the product very harmful 
o Consider the product moderately harmful 
o Consider the product slightly harmful 
o Consider the product neither safe nor harmful 
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o Consider the product slightly safe 
o Consider the product moderately safe 
o Consider the product very safe 
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Q50 How willing would you be to request the prescription pharmaceutical product from your physician? 
 
o Very unlikely 
o Unlikely 
o Somewhat unlikely 
o Neither unlikely nor likely 
o Somewhat likely 
o Likely 
o Very likely Q51 
Imagine you see the following prescription pharmaceutical product name and accompanying information during an 
advertisement for the product 
 
Altorex 
 
Altorex is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid Arthritis 
 
Q52 How familiar to you is the prescription pharmaceutical product listed above? 
 
o Very unfamiliar 
o Moderately unfamiliar 
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o Slightly unfamiliar 
o Neither familiar nor unfamiliar 
o Slightly familiar o 
Moderately familiar o Very 
familiar 
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Q53 How would you rate the novelty of the prescription pharmaceutical product listed above? 
 
o Very old 
o Moderately old 
o Slightly old 
o Neither old nor new 
o Slightly new o 
Moderately new o 
Very new 
Q54 How concerned would you be about using the prescription pharmaceutical product listed above? 
 
o Consider the product very harmful 
o Consider the product moderately harmful 
o Consider the product slightly harmful 
o Consider the product neither safe nor harmful 
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o Consider the product slightly safe 
o Consider the product moderately safe 
o Consider the product very safe 
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Q55 How willing would you be to request the prescription pharmaceutical product from your physician? 
 
o Very unlikely 
o Unlikely 
o Somewhat unlikely 
o Neither unlikely nor likely 
o Somewhat likely 
o Likely 
o Very likely  
Q56 
Imagine you see the following prescription pharmaceutical product name and accompanying information during an 
advertisement for the product 
 
Naxalon 
 
Naxalon is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid Arthritis 
 
 
 
Q57 How familiar to you is the prescription pharmaceutical product listed above? 
 
o Very unfamiliar 
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o Moderately unfamiliar 
o Slightly unfamiliar 
o Neither familiar nor unfamiliar 
o Slightly familiar o 
Moderately familiar o 
Very familiar 
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Q58 How would you rate the novelty of the prescription pharmaceutical product listed above? 
 
o Very old 
o Moderately old 
o Slightly old 
o Neither old nor new 
o Slightly new o 
Moderately new o 
Very new 
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Q59 How concerned would you be about using the prescription pharmaceutical product listed above? 
 
o Consider the product very harmful 
o Consider the product moderately harmful 
o Consider the product slightly harmful 
o Consider the product neither safe nor harmful 
o Consider the product slightly safe 
o Consider the product moderately safe 
o Consider the product very safe 
Q60 How willing would you be to request the prescription pharmaceutical product from your physician? 
 
o Very unlikely 
o Unlikely 
o Somewhat unlikely 
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o Neither unlikely nor likely 
o Somewhat likely 
o Likely 
o Very likely 
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Q61 
Imagine you see the following prescription pharmaceutical product name and accompanying information during an 
advertisement for the product 
 
Velcin 
 
Velcin is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid Arthritis 
 
 
 
Q62 How familiar to you is the prescription pharmaceutical product listed above? 
 
o Very unfamiliar 
o Moderately unfamiliar 
o Slightly unfamiliar 
o Neither familiar nor unfamiliar 
o Slightly familiar o 
Moderately familiar o 
Very familiar 
Q63 How would you rate the novelty of the prescription pharmaceutical product listed above? 
 
o Very old 
o Moderately old 
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o Slightly old 
o Neither old nor new 
o Slightly new o 
Moderately new o 
Very new 
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Q64 How concerned would you be about using the prescription pharmaceutical product listed above? 
 
o Consider the product very harmful 
o Consider the product moderately harmful 
o Consider the product slightly harmful 
o Consider the product neither safe nor harmful 
o Consider the product slightly safe 
o Consider the product moderately safe 
o Consider the product very safe 
Q65 How willing would you be to request the prescription pharmaceutical product from your physician? 
 
o Very unlikely 
o Unlikely 
o Somewhat unlikely 
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o Neither unlikely nor likely 
o Somewhat likely 
o Likely 
o Very likely Q66 
You are now going to see a series of pharmaceutical brand names. Please take a moment to pronounce each name, 
saying the name aloud or to yourself. You will then be asked to rate each pharmaceutical brand name based on how 
easy the name is to pronounce. Please make sure to rate each of the brand names before proceeding to the next. 
Q67 Please rate the following pharmaceutical brand name based on how easy the name is to 
pronounce. 
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Solotho 
       
Trivete 
       
Solatu 
       
 
Very Moderately Slightly 
Neit
 
her 
Slightly Moderately Very easy 
difficult to difficult to difficult to 
easy
 
nor 
easy to easy to to 
pronounce pronounce pronounce 
difficult to 
pronounce 
pronounce 
pronounce pronounce 
Evafir o o o o o o o 
 
 
 
 
Q68 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce. 
 
Very Moderately Slightly 
Neit
 
her 
Slightly Moderately Very easy 
difficult to difficult to difficult to 
easy
 
nor 
easy to easy to to 
pronounce pronounce pronounce 
difficult to 
pronounce 
pronounce 
pronounce pronounce 
 
 
 
 
 
Q69 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce. 
 
Very Moderately Slightly 
Neit
 
her 
Slightly Moderately Very easy 
difficult to difficult to difficult to 
easy
 
nor 
easy to easy to to 
pronounce pronounce pronounce 
difficult to 
pronounce 
pronounce 
pronounce pronounce 
 
 
 
 
 
Q70 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce. 
 
Very Moderately Slightly 
Neit
 
her 
Slightly Moderately Very easy 
difficult to difficult to difficult to 
easy
 
nor 
easy to easy to to 
pronounce pronounce pronounce 
difficult to 
pronounce 
pronounce 
pronounce pronounce 
Q71 Please rate the following pharmaceutical brand name based on how easy the name is to 
pronounce. 
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Runfina 
       
Cutrino 
       
Altorex 
       
 
Very Moderately Slightly 
Neit
 
her 
Slightly Moderately Very easy 
difficult to difficult to difficult to 
easy
 
nor 
easy to easy to to 
pronounce pronounce pronounce 
difficult to 
pronounce 
pronounce 
pronounce pronounce 
Vithoria o o o o o o o 
 
 
Q72 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce. 
 
Very Moderately Slightly 
Neit
 
her 
Slightly Moderately Very easy 
difficult to difficult to difficult to 
easy
 
nor 
easy to easy to to 
pronounce pronounce pronounce 
difficult to 
pronounce 
pronounce 
pronounce pronounce 
 
 
 
 
 
Q73 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce. 
 
Very Moderately Slightly 
Neit
 
her 
Slightly Moderately Very easy 
difficult to difficult to difficult to 
easy
 
nor 
easy to easy to to 
pronounce pronounce pronounce 
difficult to 
pronounce 
pronounce 
pronounce pronounce 
 
 
 
 
 
Q74 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce. 
 
Very Moderately Slightly 
Neit
 
her 
Slightly Moderately Very easy 
difficult to difficult to difficult to 
easy
 
nor 
easy to easy to to 
pronounce pronounce pronounce 
difficult to 
pronounce 
pronounce 
pronounce pronounce 
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Naxalon 
       
Velcin 
       
 
 
Q75 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce. 
 
Very Moderately Slightly 
Neit
 
her 
Slightly Moderately Very easy 
difficult to difficult to difficult to 
easy
 
nor 
easy to easy to to 
pronounce pronounce pronounce 
difficult to 
pronounce 
pronounce 
pronounce pronounce 
 
 
 
 
 
Q76 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce. 
 
Very Moderately Slightly 
Neit
 
her 
Slightly Moderately Very easy 
difficult to difficult to difficult to 
easy
 
nor 
easy to easy to to 
pronounce pronounce pronounce 
difficult to 
pronounce 
pronounce 
pronounce pronounce 
 
 
 
 
 
Q137 Thank you for your participation! Please provide your name and email below so payment can be processed for 
taking part in this study. 
 
 
 
 
 
Q77 
Imagine you see the following prescription pharmaceutical product name and accompanying information during an 
advertisement for the product 
 
Niyxob 
 
Niyxob is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid Arthritis 
 124  
 
 
 
Q78 How familiar to you is the prescription pharmaceutical product listed above? 
 
o Very unfamiliar 
o Moderately unfamiliar 
o Slightly unfamiliar 
o Neither familiar nor unfamiliar 
o Slightly familiar o 
Moderately familiar o 
Very familiar 
Q79 How would you rate the novelty of the prescription pharmaceutical product listed above? 
 
o Very old 
o Moderately old 
o Slightly old 
o Neither old nor new 
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o Slightly new o 
Moderately new o 
Very new 
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Q80 How concerned would you be about using the prescription pharmaceutical product listed above? 
 
o Consider the product very harmful 
o Consider the product moderately harmful 
o Consider the product slightly harmful 
o Consider the product neither safe nor harmful 
o Consider the product slightly safe 
o Consider the product moderately safe 
o Consider the product very safe 
Q81 How willing would you be to request the prescription pharmaceutical product from your physician? 
 
o Very unlikely 
o Unlikely 
o Somewhat unlikely 
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o Neither unlikely nor likely 
o Somewhat likely 
o Likely 
o Very likely 
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Q82 
Imagine you see the following prescription pharmaceutical product name and accompanying information during an 
advertisement for the product 
 
Quthutix 
 
Quthutix is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid 
Arthritis 
 
 
Q83 How familiar to you is the prescription pharmaceutical product listed above? 
 
o Very unfamiliar 
o Moderately unfamiliar 
o Slightly unfamiliar 
o Neither familiar nor unfamiliar 
o Slightly familiar o 
Moderately familiar o 
Very familiar 
Q84 How would you rate the novelty of the prescription pharmaceutical product listed above? 
 
o Very old 
o Moderately old 
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o Slightly old 
o Neither old nor new 
o Slightly new o 
Moderately new o 
Very new 
 130  
 
 
Q85 How concerned would you be about using the prescription pharmaceutical product listed above? 
 
o Consider the product very harmful 
o Consider the product moderately harmful 
o Consider the product slightly harmful 
o Consider the product neither safe nor harmful 
o Consider the product slightly safe 
o Consider the product moderately safe 
o Consider the product very safe 
Q86 How willing would you be to request the prescription pharmaceutical product from your physician? 
 
o Very unlikely 
o Unlikely 
o Somewhat unlikely 
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o Neither unlikely nor likely 
o Somewhat likely 
o Likely 
o Very likely 
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Q87 
Imagine you see the following prescription pharmaceutical product name and accompanying information during an 
advertisement for the product 
 
Oxgnue 
 
Oxgnue is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid 
Arthritis 
 
 
Q88 How familiar to you is the prescription pharmaceutical product listed above? 
 
o Very unfamiliar 
o Moderately unfamiliar 
o Slightly unfamiliar 
o Neither familiar nor unfamiliar 
o Slightly familiar o 
Moderately familiar o 
Very familiar 
Q89 How would you rate the novelty of the prescription pharmaceutical product listed above? 
 
o Very old 
o Moderately old 
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o Slightly old 
o Neither old nor new 
o Slightly new o 
Moderately new o 
Very new 
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Q90 How concerned would you be about using the prescription pharmaceutical product listed above? 
 
o Consider the product very harmful 
o Consider the product moderately harmful 
o Consider the product slightly harmful 
o Consider the product neither safe nor harmful 
o Consider the product slightly safe 
o Consider the product moderately safe 
o Consider the product very safe 
Q91 How willing would you be to request the prescription pharmaceutical product from your physician? 
 
o Very unlikely 
o Unlikely 
o Somewhat unlikely 
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o Neither unlikely nor likely 
o Somewhat likely 
o Likely 
o Very likely 
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Q92 
Imagine you see the following prescription pharmaceutical product name and accompanying information during an 
advertisement for the product 
 
Enyvfo 
 
Enyvfo is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid Arthritis 
 
 
Q93 How familiar to you is the prescription pharmaceutical product listed above? 
 
o Very unfamiliar 
o Moderately unfamiliar 
o Slightly unfamiliar 
o Neither familiar nor unfamiliar 
o Slightly familiar o 
Moderately familiar o 
Very familiar 
Q94 How would you rate the novelty of the prescription pharmaceutical product listed above? 
 
o Very old 
o Moderately old 
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o Slightly old 
o Neither old nor new 
o Slightly new o 
Moderately new o 
Very new 
 138  
 
 
Q95 How concerned would you be about using the prescription pharmaceutical product listed above? 
 
o Consider the product very harmful 
o Consider the product moderately harmful 
o Consider the product slightly harmful 
o Consider the product neither safe nor harmful 
o Consider the product slightly safe 
o Consider the product moderately safe 
o Consider the product very safe 
Q96 How willing would you be to request the prescription pharmaceutical product from your physician? 
 
o Very unlikely 
o Unlikely 
o Somewhat unlikely 
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o Neither unlikely nor likely 
o Somewhat likely 
o Likely 
o Very likely 
 140  
 
 
Q97 
Imagine you see the following prescription pharmaceutical product name and accompanying information during an 
advertisement for the product 
 
Vetlixfi 
 
Vetlixfi is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid Arthritis 
 
 
Q98 How familiar to you is the prescription pharmaceutical product listed above? 
 
o Very unfamiliar 
o Moderately unfamiliar 
o Slightly unfamiliar 
o Neither familiar nor unfamiliar 
o Slightly familiar o 
Moderately familiar o 
Very familiar 
Q99 How would you rate the novelty of the prescription pharmaceutical product listed above? 
 
o Very old 
o Moderately old 
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o Slightly old 
o Neither old nor new 
o Slightly new o 
Moderately new o 
Very new 
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Q100 How concerned would you be about using the prescription pharmaceutical product listed above? 
 
o Consider the product very harmful 
o Consider the product moderately harmful 
o Consider the product slightly harmful 
o Consider the product neither safe nor harmful 
o Consider the product slightly safe 
o Consider the product moderately safe 
o Consider the product very safe 
Q101 How willing would you be to request the prescription pharmaceutical product from your physician? 
 
o Very unlikely 
o Unlikely 
o Somewhat unlikely 
 143  
o Neither unlikely nor likely 
o Somewhat likely 
o Likely 
o Very likely 
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Q102 
Imagine you see the following prescription pharmaceutical product name and accompanying information during an 
advertisement for the product 
 
Subridke 
 
Subridke is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid 
Arthritis 
 
Q103 How familiar to you is the prescription pharmaceutical product listed above? 
 
o Very unfamiliar 
o Moderately unfamiliar 
o Slightly unfamiliar 
o Neither familiar nor unfamiliar 
o Slightly familiar o 
Moderately familiar o 
Very familiar 
Q104 How would you rate the novelty of the prescription pharmaceutical product listed above? 
 
o Very old 
o Moderately old 
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o Slightly old 
o Neither old nor new 
o Slightly new o 
Moderately new o 
Very new 
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Q105 How concerned would you be about using the prescription pharmaceutical product listed above? 
 
o Consider the product very harmful 
o Consider the product moderately harmful 
o Consider the product slightly harmful 
o Consider the product neither safe nor harmful 
o Consider the product slightly safe 
o Consider the product moderately safe 
o Consider the product very safe 
Q106 How willing would you be to request the prescription pharmaceutical product from your physician? 
 
o Very unlikely 
o Unlikely 
o Somewhat unlikely 
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o Neither unlikely nor likely 
o Somewhat likely 
o Likely 
o Very likely Q107 
Imagine you see the following prescription pharmaceutical product name and accompanying information during an 
advertisement for the product 
 
Oxibinle 
 
Oxibinle is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid 
Arthritis 
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Q108 How familiar to you is the prescription pharmaceutical product listed above? 
 
o Very unfamiliar 
o Moderately unfamiliar 
o Slightly unfamiliar 
o Neither familiar nor unfamiliar 
o Slightly familiar o 
Moderately familiar o 
Very familiar 
Q109 How would you rate the novelty of the prescription pharmaceutical product listed above? 
 
o Very old 
o Moderately old 
o Slightly old 
o Neither old nor new 
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o Slightly new o 
Moderately new o 
Very new 
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Q110 How concerned would you be about using the prescription pharmaceutical product listed above? 
 
o Consider the product very harmful 
o Consider the product moderately harmful 
o Consider the product slightly harmful 
o Consider the product neither safe nor harmful 
o Consider the product slightly safe 
o Consider the product moderately safe 
o Consider the product very safe 
Q111 How willing would you be to request the prescription pharmaceutical product from your physician? 
 
o Very unlikely 
o Unlikely 
o Somewhat unlikely 
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o Neither unlikely nor likely 
o Somewhat likely 
o Likely 
o Very likely 
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Q112 
Imagine you see the following prescription pharmaceutical product name and accompanying information during an 
advertisement for the product 
 
Oxtieze 
 
Oxtieze is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid 
Arthritis 
 
 
 
Q113 How familiar to you is the prescription pharmaceutical product listed above? 
 
o Very unfamiliar 
o Moderately unfamiliar 
o Slightly unfamiliar 
o Neither familiar nor unfamiliar 
o Slightly familiar o 
Moderately familiar o 
Very familiar 
Q114 How would you rate the novelty of the prescription pharmaceutical product listed above? 
 
o Very old 
o Moderately old 
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o Slightly old 
o Neither old nor new 
o Slightly new o 
Moderately new o 
Very new 
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Q115 How concerned would you be about using the prescription pharmaceutical product listed above? 
 
o Consider the product very harmful 
o Consider the product moderately harmful 
o Consider the product slightly harmful 
o Consider the product neither safe nor harmful 
o Consider the product slightly safe 
o Consider the product moderately safe 
o Consider the product very safe 
Q116 How willing would you be to request the prescription pharmaceutical product from your physician? 
 
o Very unlikely 
o Unlikely 
o Somewhat unlikely 
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o Neither unlikely nor likely 
o Somewhat likely 
o Likely 
o Very likely 
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Q117 
Imagine you see the following prescription pharmaceutical product name and accompanying information during an 
advertisement for the product 
 
Asbixat 
 
Asbixat is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid 
Arthritis 
 
 
Q118 How familiar to you is the prescription pharmaceutical product listed above? 
 
o Very unfamiliar 
o Moderately unfamiliar 
o Slightly unfamiliar 
o Neither familiar nor unfamiliar 
o Slightly familiar o 
Moderately familiar o 
Very familiar 
Q119 How would you rate the novelty of the prescription pharmaceutical product listed above? 
 
o Very old 
o Moderately old 
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o Slightly old 
o Neither old nor new 
o Slightly new o 
Moderately new o 
Very new 
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Q120 How concerned would you be about using the prescription pharmaceutical product listed above? 
 
o Consider the product very harmful 
o Consider the product moderately harmful 
o Consider the product slightly harmful 
o Consider the product neither safe nor harmful 
o Consider the product slightly safe 
o Consider the product moderately safe 
o Consider the product very safe 
Q121 How willing would you be to request the prescription pharmaceutical product from your physician? 
 
o Very unlikely 
o Unlikely 
o Somewhat unlikely 
 159  
o Neither unlikely nor likely 
o Somewhat likely 
o Likely 
o Very likely 
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Q122 
Imagine you see the following prescription pharmaceutical product name and accompanying information during an 
advertisement for the product 
 
Docilge 
 
Docilge is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid Arthritis 
 
 
Q123 How familiar to you is the prescription pharmaceutical product listed above? 
 
o Very unfamiliar 
o Moderately unfamiliar 
o Slightly unfamiliar 
o Neither familiar nor unfamiliar 
o Slightly familiar o 
Moderately familiar o 
Very familiar 
Q124 How would you rate the novelty of the prescription pharmaceutical product listed above? 
 
o Very old 
o Moderately old 
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o Slightly old 
o Neither old nor new 
o Slightly new o 
Moderately new o 
Very new 
 113  
Niyxob 
 
 
Q125 How concerned would you be about using the prescription pharmaceutical product listed above? 
 
o Consider the product very harmful 
o Consider the product moderately harmful 
o Consider the product slightly harmful 
o Consider the product neither safe nor harmful 
o Consider the product slightly safe 
o Consider the product moderately safe 
o Consider the product very safe 
Q126 How willing would you be to request the prescription pharmaceutical product from your physician? 
 
o Very unlikely 
o Unlikely 
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o Somewhat unlikely 
o Neither unlikely nor likely 
o Somewhat likely 
o Likely 
o Very likely 
Q127 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce. 
 
Very Moderately Slightly 
Neit
 
her 
Slightly Moderately Very easy 
difficult to difficult to difficult to 
easy
 
nor 
easy to easy to to 
pronounce pronounce pronounce 
difficult to 
pronounce 
pronounce 
pronounce pronounce 
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Quthutix 
       
Oxgnue 
       
Enyvfo 
       
Vetlixfi 
 
 
 
 
Q128 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce. 
 
Very Moderately Slightly 
Neit
 
her 
Slightly Moderately Very easy 
difficult to difficult to difficult to 
easy
 
nor 
easy to easy to to 
pronounce pronounce pronounce 
difficult to 
pronounce 
pronounce 
pronounce pronounce 
 
 
 
 
 
 
Q129 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce. 
 
Very Moderately Slightly 
Neit
 
her 
Slightly Moderately Very easy 
difficult to difficult to difficult to 
easy
 
nor 
easy to easy to to 
pronounce pronounce pronounce 
difficult to 
pronounce 
pronounce 
pronounce pronounce 
 
 
 
 
 
Q130 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce. 
 
Very Moderately Slightly 
Neit
 
her 
Slightly Moderately Very easy 
difficult to difficult to difficult to 
easy
 
nor 
easy to easy to to 
pronounce pronounce pronounce 
difficult to 
pronounce 
pronounce 
pronounce pronounce 
 
 
 
 
 
Q131 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce. 
 
Very Moderately Slightly 
Neit
 
her 
Slightly Moderately Very easy 
difficult to difficult to difficult to 
easy
 
nor 
easy to easy to to 
pronounce pronounce pronounce 
difficult to 
pronounce 
pronounce 
pronounce pronounce 
The Role of Brand Name Fluency: A Pharmaceutical Marketing Perspective 
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Oxibinle 
       
Oxtieze 
       
Asbixat 
      
 
Q132 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce. 
 
Very Moderately Slightly 
Neit
 
her 
Slightly Moderately Very easy 
difficult to difficult to difficult to 
easy
 
nor 
easy to easy to to 
pronounce pronounce pronounce 
difficult to 
pronounce 
pronounce 
pronounce pronounce 
Subridke o o o o o o o 
 
 
Q133 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce. 
 
Very Moderately Slightly 
Neit
 
her 
Slightly Moderately Very easy 
difficult to difficult to difficult to 
easy
 
nor 
easy to easy to to 
pronounce pronounce pronounce 
difficult to 
pronounce 
pronounce 
pronounce pronounce 
 
 
 
 
 
Q134 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce. 
 
Very Moderately Slightly 
Neit
 
her 
Slightly Moderately Very easy 
difficult to difficult to difficult to 
easy
 
nor 
easy to easy to to 
pronounce pronounce pronounce 
difficult to 
pronounce 
pronounce 
pronounce pronounce 
 
 
 
 
 
Q135 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce. 
 
Very Moderately Slightly 
Neit
 
her 
Slightly Moderately Very easy 
difficult to difficult to difficult to 
easy
 
nor 
easy to easy to to 
pronounce pronounce pronounce 
difficult to 
pronounce 
pronounce 
pronounce pronounce 
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Q136 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce. 
 
 
 
Very Moderately Slightly 
Neit
 
her 
Slightly Moderately Very easy 
difficult to difficult to difficult to 
easy
 
nor 
easy to easy to to 
pronounce pronounce pronounce 
difficult to 
pronounce 
pronounce 
pronounce pronounce 
Docilge    o o o o o o o 
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